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“I am among those who think that science has great beauty. A 
scientist in his laboratory is not only a technician: he is also a child 
placed before natural phenomena which impress him like a fairy tale.” 
 
                     Maria Sklodowska-Curie 
 
 
 
 
Abstract 
Insulin resistance is characterized by a blunted biological response to insulin, and it is the 
hallmark of obesity and type 2 diabetes. Since skeletal muscle is among the major 
metabolic organs in the body, a better understanding of the molecular pathways regulating 
metabolic responses in muscle will help to develop novel strategies to improve glucose 
and lipid metabolism. Here, two different models of human skeletal muscle, intact skeletal 
muscle strips and primary human myotubes, were used to study acute regulation of 
metabolism. Globular adiponectin modestly increased glucose transport in type 2 diabetic, 
but not in nondiabetic muscle strips, without any effects on proximal insulin signaling. 
Insulin sensitizing drug rosiglitazone did not affect glucose transport or proximal insulin 
signaling events in intact human muscle strips, but it transiently activated AMPK-
signaling pathway. Polyphenolic compound resveratrol inhibited fatty acid oxidation, 
glucose metabolism and insulin signaling in human myotubes. Moreover, resveratrol 
increased ER stress and directly inhibited AMPK activity. Palmitate impaired glucose 
metabolism and increased ER stress in primary human myotubes and also in intact skeletal 
muscle strips from overweight, but not lean men. Thus, the role of ER stress in the 
pathogenesis of fatty acid induced insulin resistance and T2D warrants further studies. 
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1 Introduction 
Type 2 diabetes mellitus (T2DM) accounts for 90 % of diabetes cases around the world. It 
is a life-long condition that can lead to severe medical complications, which include 
cardiovascular disease, renal failure, blindness, neuropathy, and suspectibility to infections 
which together with compromised circulation in lower extremities may lead to gangrene 
and leg amputations. Both genetic and environmental factors contribute to the 
development of type 2 diabetes. Obesity, sedentary lifestyle, and diet with excessive 
saturated fatty acid content are the main nongenetic reasons for type 2 diabetes pandemic. 
Insulin resistance is the hallmark of common metabolic diseases such as obesity and type 
2 diabetes and is associated with defects in whole body glucose and lipid metabolism. 
Thus, it is important to identify the molecular mechanism underlying insulin resistance. 
This information will help to prevent the development of type 2 diabetes and to improve 
glucose and lipid homeostasis in afflicted patients.   
 
The skeletal muscle is the main tissue responsible for whole body glucose metabolism and 
therefore plays an important role in the development of insulin resistance. Increased 
intramuscular fat content has been hypothesized to induce insulin resistance via generation 
of active fatty acid-derived metabolites, which can interfere with insulin signal 
transduction. Moreover, inflammatory state that is present in obesity, and increased 
production of proinflammatory cytokines may also negatively affect insulin action in 
skeletal muscle. Recently, endoplasmic reticulum stress has been introduced as one of the 
central mechanisms leading to insulin resistance.  
  
AMP-activated protein kinase (AMPK) is a cellular energy sensor that acts as a master 
regulator of energy balance. Many hormones, such as leptin and adiponectin regulate 
metabolism via AMPK. Until recently, TZD:s were commonly used drugs to treat type 2 
diabetes. However, their molecular mechanism of action in skeletal muscle is unclear. It 
has been hypothesized that they may directly affect AMPK activity. In addition, 
polyphenols, such as resveratrol that is present in grapes and red wine, have been proposed 
to improve insulin sensitivity via activation of AMPK signaling cascade.  Finally, AMPK 
is known to stimulate glucose metabolism independent of the insulin signaling pathway. 
 
 
 
 
14 
These data highlight AMPK activation as an attractive pharmacological target to treat 
insulin resistance. 
 
The aim of this thesis has been to examine the regulation of glucose and fatty acid 
metabolism in human skeletal muscle. More specifically, the acute direct effects of the 
adipokine adiponectin and the antihyperglycaemic drug rosiglitazone, two insulin 
sensitizing compounds, on glucose transport and metabolic signaling pathways have been 
examined in intact human skeletal muscle. In addition, the effects of the polyphenolic 
compound resveratrol on glucose and lipid metabolism and its potential effect on AMPK 
activity have been studied in human skeletal muscle cells.  
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2 Review of the literature 
2.1 Insulin signaling in skeletal muscle 
Whole body glucose homeostasis is regulated by the hormone insulin, which is secreted 
by β-cells in the pancreatic islets of Langerhans in response to a rise in plasma glucose 
concentration. Insulin promotes glucose transport and oxidation and regulates protein, 
glycogen and triacylglycerol metabolism in target tissues such as skeletal muscle and 
adipose tissue. Skeletal muscle is responsible for ~80 % of whole body glucose uptake in 
insulin-stimulated conditions and thus it is an important tissue to study the mechanism of 
defects in insulin signaling and action (DeFronzo, Jacot et al. 1981; Ferrannini, Simonson 
et al. 1988). 
2.1.1 Insulin receptor 
Insulin signaling events are initiated by binding of insulin to its receptor (IR). This results 
in rapid autophoshorylation of the receptor (White and Kahn 1994). The insulin receptor is 
a transmembrane heterotetrameric glycoprotein, which belongs to the tyrosine kinase 
receptor family. IR consists of two extracellular α-subunits, which possess the ability to 
bind insulin, and two intracellular β-subunits that contain the tyrosine kinase domain 
(White and Kahn 1994). Insulin binding to its receptor leads to conformational changes in 
α-subunits and subsequent activation of the tyrosine kinase in the β-subunit. The IR is 
autophosphorylated in at least six residues, where Tyr960 plays the most important role in 
the regulation of glucose homeostasis (White and Kahn 1994). Tyr960 is located in the 
juxtamembrane region of the insulin receptor. This site is recognized by the insulin 
receptor substrate (IRS) proteins (1-6 isoforms) (Cai, Dhe-Paganon et al. 2003), Gab-1 
(Holgado-Madruga, Emlet et al. 1996) and Shc (Craparo, O'Neill et al. 1995; Gustafson, 
He et al. 1995). These proteins are critical mediators of downstream insulin signaling 
events in skeletal muscle. IRS-1 and its homologue IRS-2 are the most important insulin 
receptor substrates in the regulation of glucose and lipid homeostasis. IRS molecules 
consist of pleckstrin homology domain (PH), which is followed by phosphotyrosine-
binding (PTB) domain that is critical for the interaction with the insulin receptor. The 
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carboxy-terminal tail of IRS contains several tyrosine phosphorylation sites that are 
responsible for recruiting effector proteins such as the phosphatidyl inositol 3-kinase 
(PI3K) and the phosphatase SHP2 (White 2003).  
 
Figure 1. Insulin signaling cascades. 
 
 
2.1.1 The PI 3-kinase pathway 
The phosphatidylinositol 3-kinases (PI3Ks) are involved in the regulation of a wide range 
of physiological processes, including insulin-mediated glucose transport in skeletal muscle 
in rodents (Lund, Holman et al. 1995) as well as in humans (Shepherd, Nave et al. 1997). 
Depending on its sequence homology and substrate affinity, PI3Ks are divided into three 
classes (I-III) (Engelman, Luo et al. 2006). Class I PI3K is a heterodimeric protein 
consisting of a p85 regulatory/adapter subunit and a p110 catalytic subunit. Class I PI3K 
plays an important role in terms of insulin signaling and glucose homeostasis (Rameh and 
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Cantley 1999; Engelman, Luo et al. 2006). The role of the class II and III PI3Ks is still 
poorly understood. 
 
After insulin stimulation tyrosine phosphorylated IRS proteins bind to the regulatory 
subunit (p85) of the class I PI3K. This activates the catalytic subunit p110 and leads to the 
phosphorylation of membrane phospholipids and phosphatidylinositol- 4, 5- bisphosphate 
(PIP2) on the 3’ position (Vollenweider 2003; Engelman, Luo et al. 2006) (Figure 1). The 
formation of phosphatidylinositol- 3, 4, 5- trisphosphate leads to the activation of 3- 
phosphoinositide dependent protein kinase (PKD- 1 and PKD- 2). PKD regulates 
downstream phosphorylation of Akt/protein kinase B (PKB) and atypical isoforms of 
protein kinase C (aPKC), which are dependent neither on diacylglycerol (DAG) nor Ca2+  
(Cantley 2002; Saltiel and Pessin 2002; Vollenweider 2003; Engelman, Luo et al. 2006).  
 
AKT/protein kinase B (PKB) 
The serine/threonine kinase AKT possesses a N-terminal PH domain that is followed by a 
catalytic kinase domain and a C-terminal tail. There are three isoforms of AKT: AKT1, 
AKT2 and AKT3 (AKTα, AKTβ, AKTγ, respectively), which are expressed ubiquitously 
(Bjornholm and Zierath 2005; Kim and Novak 2007). AKT1 is the major isoform 
expressed in muscle, whereas AKT2 expression has been shown to be predominant in 
adipocytes (Walker, Deak et al. 1998). AKT3 has been shown to be expressed mainly in 
the brain and it is not activated in muscle or adipose tissue in response to insulin (Konishi, 
Kuroda et al. 1995; Walker, Deak et al. 1998). The activation of AKT requires 
phosphorylation at two specific sites, Thr308 that is localized in the kinase domain (for 
AKT1 isoform) and Ser473 in the C-terminal domain (for AKT1 isoform). PDK1 has been 
identified as the kinase responsible for the phosphorylation at the Thr308 site. The 
mechanism that leads to the phosphorylation of AKT at Ser473 is not well understood; 
PDK1 and PDK2, as well as autophosphorylation of AKT may be involved (Hajduch, 
Litherland et al. 2001; Vollenweider 2003).  
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Targets of AKT 
AKT has been demonstrated to act as an anti-apoptotic kinase, which has a crucial role in 
cell survival. AKT regulates the activity of proteins that are involved in apoptosis 
including BAD, members of the forkhead family of transcription factors and transcription 
factor NF-κB. Importantly, AKT is involved in the regulation of metabolic events such as 
glucose metabolism in skeletal muscle and adipocytes (Hajduch, Litherland et al. 2001; 
Vollenweider 2003). Glycogen synthase kinase -3 (GSK-3), which controls glycogen and 
protein synthesis among many other cellular processes, was one of the first described 
physiological targets of AKT (Cross, Alessi et al. 1995). GSK-3 possesses two isoforms, 
GSK-3α and GSK-3β, which remain active in the basal, unstimulated state. Upon insulin 
stimulation, the activity of GSK-3 is inhibited via phosphorylation at Ser21 or Ser9 (GSK-
3α and GSK-3β, respectively). This event is mediated through the PI3K-AKT signaling 
pathway. Moreover, insulin-stimulated inhibition of GSK promotes dephosphorylation 
and theryby activation of the glycogen synthase (GS), which leads to stimulation of 
glycogen synthesis (Grimes and Jope 2001).  
 
Glucose uptake is another important process that is regulated by insulin via the PI3K-AKT 
pathway in skeletal muscle (Hajduch, Alessi et al. 1998; Wang, Somwar et al. 1999; 
Karlsson, Ahlsen et al. 2006) and adipocytes (Kohn, Summers et al. 1996; Foran, Fletcher 
et al. 1999; Bai, Wang et al. 2007). AKT promotes translocation of the insulin dependent 
glucose transporter GLUT4 from the intracellular space to the plasma membrane.  Several 
studies have indicated that this process is mediated by the downstream target of AKT, 
AKT substrate 160 (AS160), which is phosphorylated at five crucial residues (Ser318, 
Ser570, Ser588, Thr642, and Thr751) in response to insulin (Sano, Kane et al. 2003; Zeigerer, 
McBrayer et al. 2004).  
 
aPKC 
Protein kinase C isoforms are important intracellular molecules that control many cellular 
events such as cell growth, cell differentiation, glucose and lipid metabolism. PKCs are 
divided into three classes according to their domain structure and regulation: conventional 
(cPKC), novel (nPKC) and atypical (aPKC) (Bertram and Ley 2011; Turban and Hajduch 
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2011). Conventional and novel PKCs are usually activated by diacylglycerol (DAG) and 
have been shown to have a negative impact on insulin signaling. Their role in the 
regulation of insulin signaling will be discussed later (Hotamisligil 2006). The aPKCs 
(aPKCλ/ζ), which lack the structural domains that bind lipids and Ca2+, are regulated by 
PDK1, the downstream target of PI3K.  In skeletal muscle (Etgen, Valasek et al. 1999) 
and adipocytes (Kotani, Ogawa et al. 1998) the overexpression of aPKC leads to an 
increase in both basal and insulin-stimulated glucose transport. In addition, muscle 
specific deletion of both isoforms of aPKCs affects insulin-stimulated glucose transport, 
as well as GLUT4 translocation (Farese, Sajan et al. 2007). Thus, these data suggest that 
aPKCs are also involved in the direct stimulation of GLUT4 transporter, independent from 
AKT. 
2.1.2 MAPK pathways 
Apart from the PI3K pathway insulin controls another well-characterized signaling 
cascade, which is known as the Ras/ERK (or mitogen activated protein kinase - MAPK) 
pathway (Figure 1). The MAPK pathway is activated in response to insulin and growth 
factors, such as IGF1, but also in response to cellular stress (Widegren, Ryder et al. 2001).  
 
Recruitment of the signaling target Shc as well as IRS to the insulin receptor (IR), 
activates the Ras/ERK cascade. Both Shc and IRS proteins bind to the adaptor GRB2 
protein that is in complex with the mSOS protein (Weng, Smith et al. 2001). The mSOS 
protein, a p21ras guanine nucleotide exchange factor (ras-GNRF), facilitates the conversion 
of inactive Ras-GDP to active Ras-GTP (Downward 1996). This leads to the 
phosphorylation of Raf and downstream activation of ERK 1 and ERK 2 (MAPK 1 and 
MAPK 2, respectively (Blenis 1993; Widegren, Ryder et al. 2001). Activated ERKs 
regulate a number of transcription events that are involved in DNA synthesis and cell 
cycle progression. For instance, ERKs phoshorylate Elk-1, a transcription activator which 
mediates the expression of immediate early genes including c-fos (Blenis 1993).  
2.1.3 CAP/Cbl/TC10 pathway 
A decade ago a novel signaling pathway, CAP/Cbl/TC10 pathway, that mediates insulin 
signaling independent of the PI3K-AKT pathway, was described (Baumann, Ribon et al. 
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2000; Chiang, Baumann et al. 2001). The CAP/TC10 pathway is involved in the 
regulation of glucose transport in adipocytes (Baumann, Ribon et al. 2000; Chiang, 
Baumann et al. 2001). The CAP protein (Cbl-associated protein), which is expressed 
mostly in insulin sensitive tissues, functions as an adaptor protein for Cbl. Cbl 
phosphorylation leads to dissociation of the CAP/Cbl-complex from the IR, its 
translocation to caveolae compartments of the cell membrane and activation of TC10, a 
small GTP binding protein belonging to the Rho-family. TC10 regulates the translocation 
of the GLUT 4 transporter synergistically with PI3K (Chiang, Baumann et al. 2001). 
However, the role of the CAP/Cbl/TC10 pathway in metabolic regulation in skeletal 
muscle is not yet well understood.  
2.1.4 Defects in insulin signaling and metabolism in human skeletal muscle 
Skeletal muscle insulin resistance is an early defect in Type 2 diabetes (DeFronzo, Jacot et 
al. 1981; DeFronzo and Tripathy 2009). Therefore, a deeper understanding of the 
mechanisms which lead to dysregulation of insulin action in muscle may play a significant 
role in drug development. Several techniques have been employed to study molecular 
events that occur in skeletal muscle in insulin resistant states. A widely used in vivo 
method to measure insulin action is the euglycaemic hyperinsulinemic clamp. This 
technique is the golden standard to study whole body insulin action, and it can be 
combined with muscle biopsies, which further allow to study molecular events involved in 
insulin resistance (DeFronzo and Tripathy 2009). However, to gain more insight into the 
events underlying insulin resistance, independent of systemic factors such as ambient 
glycaemia, hyperlipidemia or circulating cytokines, direct in vitro techniques to study 
glucose metabolism and insulin action are necessary. In 1988, the method employing in 
vitro muscle preparation was described for the first time by Dohm et al. (Dohm, Tapscott 
et al. 1988). Human primary muscle cells provide another widely used experimental tool 
to investigate impairments in metabolic regulation and insulin signaling pathway. Primary 
human muscle cells possess the features of mature muscle tissue and importantly their 
diabetic phenotype is sustained in culture (Gaster, Petersen et al. 2002).  
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Defects in the early insulin signaling 
The data regarding phosphorylation of IR in obese and type 2 diabetic subjects remain 
contradictory. There is a correlation between the expression of IR and obesity (Goodyear, 
Giorgino et al. 1995). Moreover, the IR autophosphorylation was impaired in abdominal 
skeletal muscle obtained from lean diabetic subjects (Maegawa, Shigeta et al. 1991). The 
results from euglycaemic clamp studies showed a modest impairment in IR kinase activity 
in nondiabetic obese, whereas obese type 2 diabetic patients demonstrated a significant 
decrease in comparison to healthy lean or nondiabetic obese people (Nolan, Freidenberg et 
al. 1994). On the other hand, Krook et al. reported no impairment in the IR 
autophosphorylation in overweight type 2 diabetic men in comparison to healthy lean men 
(Krook, Bjornholm et al. 2000). Furthermore, subsequent studies reported no changes in 
the IR activation (Meyer, Levin et al. 2002; Kim, Kotani et al. 2003). Thus, it appears that 
major defects in the insulin signaling cascade occur downstream of IR. 
 
IRS-1 and IRS-2, the major downstream targets of IR, are the predominant IRS isoforms 
that are expressed in skeletal muscle. Reduced insulin-stimulated phosphorylation of IRS-
1 has been demonstrated in muscles from type 2 diabetic subjects during 
hyperinsulinaemic clamps in vivo, as well as in vitro in the muscle strip preparation (Cusi, 
Maezono et al. 2000; Krook, Bjornholm et al. 2000; Kim, Kotani et al. 2003). The human 
IRS-1 protein possesses over 20 potential tyrosine phosphorylation sites and more than 30 
serine/threonine phosphorylation sites, which play a crucial role in the regulation of the 
IRS activity (Bjornholm and Zierath 2005; Frojdo, Vidal et al. 2009). The phosphorylation 
of the IRS-1 at Ser312 (Ser309 in rats) has been implicated in the negative regulation of the 
insulin signaling cascade in cell and animal models, as well as in type 2 diabetic patients 
(Aguirre, Uchida et al. 2000; Bandyopadhyay, Yu et al. 2005; Taniguchi, Emanuelli et al. 
2006). The phosphorylation of IRS at this serine residue leads to decreased IRS tyrosine 
phosphorylation, with consequent impaired activation of PI3K (Bandyopadhyay, Yu et al. 
2005). A number of serine/threonine kinases, including c-Jun N-terminal kinase (JNK), an 
inhibitor of NFκB kinase (IKK) and protein kinase C, which have been demonstrated to 
have increased activity in obesity and type 2 diabetes, have been reported to diminish 
insulin action by serine phosphorylation of IRS-1 (Hotamisligil 2006).   
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The involvement of IRS-2 in the regulation of insulin action is poorly understood. In 
contrast to IRS-1, which is centrally involved in the regulation of glucose metabolism, 
IRS-2 regulates lipid metabolism and the MAPK signaling pathway in primary human 
skeletal muscle cells (Bouzakri, Zachrisson et al. 2006). A decrease in IRS-2-associated 
PI3K activity has been reported in human skeletal muscle obtained from diabetic subjects 
(Kim, Nikoulina et al. 1999). Further studies are needed to investigate the metabolic role 
of IRS-2 in human skeletal muscle. 
 
Defects in the PI3K pathway 
The phosphatidyl inositol-3 kinase (PI3K) plays a crucial role in insulin-mediated signal 
transduction, and controls glucose uptake and GLUT4 translocation. Alterations in PI3K 
activity in human skeletal muscle from type 2 diabetic subjects have been described in a 
number of independent in vivo and in vitro studies (Bjornholm, Kawano et al. 1997; Kim, 
Nikoulina et al. 1999; Krook, Bjornholm et al. 2000; Bandyopadhyay, Yu et al. 2005).  
 
Data regarding defects in AKT activity in obese and type 2 diabetic patients have been 
controversial. Significant defects in the phosphorylation of AKT at Ser473 or Thr308 in 
skeletal muscle obtained from type 2 diabetic patients have been described (Krook, Roth 
et al. 1998; Meyer, Levin et al. 2002; Karlsson, Zierath et al. 2005; Cozzone, Frojdo et al. 
2008). However, other investigators have found no changes in the phosphorylation or 
activity of AKT in type 2 diabetic people (Kim, Nikoulina et al. 1999; Krook, Bjornholm 
et al. 2000). Any impairment in the AKT phosphorylation at the level of the specific 
phosphorylation site is also unclear. It has been reported that the phosphorylation of 
AKT473 is unaltered, while the phosphorylation of AKT308 is significantly decreased in 
skeletal muscle from type 2 diabetic subjects (Karlsson, Zierath et al. 2005). On the other 
hand, Cozzane et al. reported a decrease in insulin-stimulated phosphorylation at Ser473, 
but not at Thr308 in skeletal muscle of Type 2 diabetic subjects during hyperinsulinaemic-
euglycaemic clamp (Cozzone, Frojdo et al. 2008). The differences in the activity of AKT 
might be explained by isoform-specific defects, as most of the studies mentioned above 
have measured the global phosphorylation of AKT. Isoform specific impairments of 
AKT2 and AKT3, but not AKT1 in response to insulin have been observed in skeletal 
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muscle obtained from morbidly obese insulin resistant subjects (Brozinick, Roberts et al. 
2003). In addition, a decrease in the phosphorylation of AKT2 at Ser473 and AKT1 at 
Thr308 has been reported in human primary muscle cells from Type 2 diabetic patients 
(Cozzone, Frojdo et al. 2008). The variability of AKT activation can also be due to 
different experimental models (muscle biopsy, muscle strips and primary cells) and 
experimental conditions (normoglycaemia and hyperglycaemia), but can also be due to 
subject characteristics, which has not been comparable in most studies.  
 
AS160 is a downstream target of AKT, and links PI3K/AKT signaling to GLUT4 
translocation. The insulin-stimulated phosphorylation of AS160 is significantly decreased 
in skeletal muscle from type 2 diabetic subjects (Karlsson, Zierath et al. 2005). Infusion of 
TNF-α, a well-known cytokine to induce insulin resistance, was also positively correlated 
with impaired AS160 phosphorylation in healthy subjects (Plomgaard, Bouzakri et al. 
2005). Several studies have reported defects in GLUT4 translocation from the intracellular 
pool to the cellular membrane in human skeletal muscle from T2D patients (Ryder, Yang 
et al. 2000; Koistinen, Galuska et al. 2003). Recently, the hypothesis of involvement of 
AS160 in GLUT4 translocation has been proven in 3T3-L1 adipocytes (Eguez, Lee et al. 
2005) and L6 cells (Thong, Bilan et al. 2007). Additionally, impairments in glucose 
transport correlated with decrease in phosphorylation of AS160 in skeletal muscle from 
type 2 diabetic men (Karlsson, Ahlsen et al. 2006). 
 
GLUT4 translocation and subsequent increases in glucose transport are also stimulated in 
an insulin-dependent manner by aPKCs, which operate downstream of PI3K and its lipid 
product PIP3. However, the data regarding the role of aPKCs in human skeletal muscle are 
limited. In subjects with impaired glucose tolerance (IGT), which is considered a 
prediabetic state, and in subjects with type 2 diabetes, aPKC activation during the 
hyperinsulinaemic euglycaemic clamp is markedly decreased (Beeson, Sajan et al. 2003). 
In cultured myotubes from IGT subjects, there is a significant reduction of aPKC activity 
in response to insulin. This is also associated with impaired glucose uptake (Vollenweider, 
Menard et al. 2002).  
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Defects in glucose transport and glycogen synthesis 
During the euglycaemic hyperinsulinaemic clamp, 20-25 % of glucose is utilized in 
skeletal muscle to produce energy in glycolytic processes, where glucose is oxidized to 
CO2 and H2O via the citric acid cycle, ultimately leading to generation of ATP. However, 
the major part, ~75-80 % of glucose disposal is accounted for by nonoxidative glucose 
metabolism where glucose is converted into glycogen and stored for later energy 
utilization (DeFronzo and Tripathy 2009). Impaired glycogen synthesis and reduced 
glycogen synthase activity are considered among the earliest detectable metabolic defects 
in type 2 diabetes (Bogardus, Lillioja et al. 1984; Shulman, Rothman et al. 1990). 
However, impaired insulin stimulated glucose transport is the key rate-limiting step in the 
reduced glycogen synthesis and glucose uptake in the insulin resistant state (Cline, 
Petersen et al. 1999).  
 
Glucose is a hydrophilic molecule and has to diffuse into the cell via a lipid bilayer. This 
is mediated by membrane transporter proteins, such as GLUTs that facilitate glucose 
uptake. To date, at least 14 GLUTs have been described (GLUT 1-14) (Vollenweider 
2003). In skeletal muscle, GLUT1 is responsible for mediating basal glucose transport, 
whereas GLUT4 controls the major part of the insulin-stimulated glucose transport 
(Tordjman, Leingang et al. 1989). Insulin-stimulated glucose transport is reduced in 
skeletal muscle obtained from type 2 diabetic subjects. While the total protein content of 
GLUT 4 is unchanged in these subjects, the protein content at the cell surface is markedly 
reduced (Bouzakri, Koistinen et al. 2005).  
 
2.2 AMP –activated protein kinase pathway 
2.2.1 The structure and regulation of AMPK 
AMP-activated protein kinase (AMPK) plays a major role in the regulation of whole body 
energy balance and constitutes an alternative, noninsulin-dependent pathway to improve 
glucose and lipid metabolism. In skeletal muscle and adipose tissue, AMPK is activated 
by the action of various adipokines, such as leptin and adiponectin, as well as by changes 
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in the AMP/ATP ratio (for example during glucose deprivation or hypoxia) and cellular 
concentration of Ca2+, which are linked to energy deprivation (Zhang, Zhou et al. 2009).  
 
AMPK is a heterotrimeric enzyme composed of the catalytic subunit α1 or α2, and two 
regulatory subunits (β1 or β2, and γ1, γ2 or γ3). AMPK is activated via the 
phosphorylation at Thr172 at the catalytical α subunit (Zhang, Zhou et al. 2009). This 
critical step is needed for the maximal activation of the enzyme and is limited by upstream 
kinases like LKB1, calcium/calmodulin dependent protein kinase β (CaMKKβ) and 
mammalian transforming growth factor β-activated kinase (TAK1) (Hawley, Pan et al. 
2005; Hurley, Anderson et al. 2005; Momcilovic, Hong et al. 2006). The role of the 
different kinases involved in the activation of AMPK is still unresolved. Nevertheless, 
there is compelling evidence that LKB1 is required for the regulation of AMPK in 
response to changes in AMP/ATP ratio.  The γ-subunit of AMPK possesses four CBS 
(cystathionine-β-synthase) domains, which are involved in AMP binding. Binding of 
AMP to AMPK activates the enzyme allosterically, as well as inhibits the 
dephosphorylation of AMPK at Thr172. In addition, constitutively active LKB1 leads to 
increases in phosphorylation at Thr172, since the dephosphorylation is inhibited (Sanders, 
Grondin et al. 2007).  
2.2.2 Downstream targets of AMPK in skeletal muscle 
In skeletal muscle, the activation of AMPK occurs mainly in response to contraction and it 
is linked with increased energy demand and ATP turnover. AMPK regulates a number of 
metabolic processes in skeletal muscle, including fatty acid oxidation, glucose transport, 
and glycogen synthesis as well as mitochondrial biogenesis.  
 
Fatty acid oxidation 
AMPK regulates fatty acid (FA) oxidation in skeletal muscle via the malonyl-CoA 
signaling network (Figure 2). Malonyl-CoA is an allosteric inhibitor of carnitine 
palmitoyltransferase 1 (CPT-1), the enzyme that controls the transfer of long-chain fatty 
acids into the mitochondria (Koh, Brandauer et al. 2008).  
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Activation of AMPK leads to an increases in fatty acid oxidation via phosphorylation and 
inactivation of ACC2 isoform, which is involved in the production of malonyl-CoA 
(Winder and Hardie 1996; Dean, Daugaard et al. 2000). During exercise, AMPK inhibits 
ACC and the production of malonyl-CoA and thereby activates downstream CPT-1. This 
promotes fatty acid uptake into the mitochondria and hence FA oxidation (Hardie 2011). 
In addition, AMPK stimulates FA oxidation through the activation of malonyl-CoA 
decarboxylase, which catalyzes decarboxylation and degradation of malonyl-CoA (Saha, 
Schwarsin et al. 2000). Activation of AMPK reduces elevated free fatty acids and 
intramuscular triglycerol content in skeletal muscle. Thefore, AMPK plays an important 
regulatory role in insulin sensitivity.  
 
Regulation of glucose transport 
Apart from FA oxidation (Figure 2), AMPK is involved in the stimulation of glucose 
transport that is independent of insulin, but has an additive effect to insulin action. Studies 
have shown that physical activity or pharmacological compounds that mimic exercise can 
increase GLUT 4 translocation and glucose transport in skeletal muscle from rodents and 
humans (Kurth-Kraczek, Hirshman et al. 1999; Fryer, Foufelle et al. 2002; Koistinen, 
Galuska et al. 2003). The mechanisms that lead to stimulation of glucose transport by 
AMPK are incompletely understood. It has been proposed that AMPK phosphorylates 
AS160 (TBC1D1) in human skeletal muscle. However, recent studies have introduced 
TBC1D4 as the main target of AMPK that links the activation of the enzyme to glucose 
transport. Importantly, AMPK can also promote glucose transport by increasing the 
activity of the GLUT1 transporter in muscle cells (Fryer, Foufelle et al. 2002). In addition, 
chronic activation of AMPK promotes gene transcription of the GLUT4 transporter 
(Zheng, MacLean et al. 2001). 
 
 Glycogen synthesis 
Glycogen synthase (GS), the enzyme that controls the last step of glycogen synthesis, is 
one of the targets of AMPK. GS activity is reduced through phosphorylation at Ser7, 
which is mediated by AMPK. This leads to a decrease in glycogen synthesis (Jorgensen, 
Nielsen et al. 2004). Interestingly, the β-subunit of AMPK possesses the ability to bind 
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glycogen (Hudson, Pan et al. 2003; Polekhina, Gupta et al. 2003) and it has been 
suggested that glycogen itself can inhibit AMPK activity (McBride, Ghilagaber et al. 
2009). However, the mechanism of glycogen regulation on AMPK activity is still poorly 
understood.  
 
 
Figure 2. AMPK signaling pathway.  
 
Mitochondrial biogenesis 
AMPK has also been shown to upregulate the expression of the transcriptional co-
activator PPARγ co-activator-1α (PGC-1α), which promotes the expression of genes 
involved in mitochondrial biogenesis (Hardie 2011). Although it has been reported that 
AMPK has a direct effect on PGC-1α phosphorylation in skeletal muscle (Jager, 
Handschin et al. 2007), the mechanism may involve deacetylation of PGC-1α by Sirt1, 
which acts downstream of AMPK (Canto, Gerhart-Hines et al. 2009; Canto, Jiang et al. 
2010). 
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2.2.3 AMPK activators 
2.2.3.1 Physiological activators 
Leptin 
Leptin is secreted by adipocytes and this hormone is involved in the regulation of 
numerous metabolic processes including glucose and lipid metabolism, as well as food 
intake. Leptin has been shown to activate AMPK in skeletal muscle, which is linked with 
the stimulatory effect of leptin on glucose transport and lipid oxidation (Minokoshi, Kim 
et al. 2002). Moreover, leptin has a positive impact on insulin sensitivity by preventing 
lipid accumulation in peripheral tissues such as skeletal muscle. Chronic treatment with 
leptin decreases the triacyglycerol content in skeletal muscle from rodents on high fat diet 
and this is associated with improvements in insulin-stimulated glucose uptake and 
glycogen synthesis (Yaspelkis, Singh et al. 2004). However, obesity is a leptin resistant 
state, as indicated by high levels of circulating leptin in obese humans and rodents 
(Maffei, Halaas et al. 1995; Considine, Sinha et al. 1996). Treatment of obese patients 
with leptin does not have an effect on weight loss (Heymsfield, Greenberg et al. 1999). 
Taken together, these data suggest that obese humans are resistant to both endogenous and 
exogenous leptin.  
 
Adiponectin 
Adiponectin is a 30 kDa adipokine that activates AMPK. Adiponectin enhances insulin 
sensitivity in skeletal muscle and liver from animals by affecting glucose and lipid 
metabolism (Tomas, Tsao et al. 2002; Yamauchi, Kamon et al. 2002). Under physiological 
conditions plasma concentrations of adiponectin account for 0.01 % of total proteins in 
humans (Dyck, Heigenhauser et al. 2006). Several lines of evidence indicate that lower 
levels of circulating adiponectin are associated with obesity and type 2 diabetes in rodents 
and humans (Hu, Liang et al. 1996; Arita, Kihara et al. 1999; Hotta, Funahashi et al. 2001; 
Ryo, Nakamura et al. 2004). In skeletal muscle, globular adiponectin (gAd) regulates fatty 
acid oxidation via increased phosphorylation of AMPK and its downstream target ACC 
(Yamauchi, Kamon et al. 2002; Ceddia, Somwar et al. 2005). Moreover, adiponectin 
enhances GLUT4 translocation and glucose transport independently from the insulin 
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signaling cascade, suggesting that other pathways, such as AMPK, are involved in the 
mechanism of gAd action (Ceddia, Somwar et al. 2005). To date, there have been only a 
few studies that have addressed the effect of gAd on metabolism in human skeletal 
muscle. In cultured myotubes obtained from obese subjects, the phosphorylation of 
AMPK and FA oxidation are blunted at low gAd concentration. In myotubes from diabetic 
subjects high adiponectin concentrations are able to activate AMPK, but there are no 
changes in the phosphorylation of ACC or FA oxidation (Chen, McAinch et al. 2005). In 
human skeletal muscle strips from obese individuals, fatty acid oxidation is not affected 
by exposure to globular adiponectin. Although there is no difference in the glucose 
transport rate between obese and lean women in response to gAd, the additive effect of 
gAd on insulin action is impaired in obese individuals (Bruce, Mertz et al. 2005). In 
summary, these data suggest the presence of adiponectin resistance in obesity and type 2 
diabetes. The mechanism of adiponectin resistance remains unknown. However, it is 
unlikely to be dependent on changes in the AdipoR1 receptor expression (Thrush, 
Heigenhauser et al. 2008; Mullen, Pritchard et al. 2009).  
2.2.3.2 Pharmaceutical activators 
TZDs 
Thiazolidinediones (TZDs), such as rosiglitazone or pioglitazone, were widely used 
therapeutic agents to treat type 2 diabetes before the concerns regarding cardiovascular 
risks led to withdrawal of rosiglitazone (Quinn, Hamilton et al. 2008). TZDs are known to 
enhance insulin sensitivity by improving glucose disposal and inhibiting gluconeogenesis. 
TZDs improve insulin action via activation of proliferator-activated receptor- γ (PPAR- γ), 
a transcription factor that is highly expressed in adipocytes. The activation of PPAR-γ in 
adipose tissue leads to increased differentiation of adipocytes and formation of smaller 
adipocytes that are more sensitive to insulin. However, it has been suggested that TZDs 
may have direct metabolic effects on skeletal muscle independent of the activation of 
PPAR- γ. Treatment of transgenic mice with no adipose tissue or with muscle specific 
PPAR- γ deletion with TZD promotes insulin sensitivity (Burant, Sreenan et al. 1997; 
Norris, Chen et al. 2003). In addition, in intact skeletal muscle from rat TZDs activate 
AMPK and stimulate glucose uptake and lipid oxidation (LeBrasseur, Kelly et al. 2006). 
In human primary muscle cells obtained form type 2 diabetic subjects treatment with 
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different TZDs improves fatty acid metabolism and decreases the activation of ACC, a 
downstream target of AMPK (Cha, Ciaraldi et al. 2005). 
 
AICAR 
The pharmacological compound AICAR (5-aminoimidazole-4-carboxamide-1-β-D-
ribonucleoside) is the precursor of ZMP, which mimics AMP and thus activates AMPK in 
a similar fashion as for example an increase in AMP to ATP-ratio during exercise. 
Treatment with AICAR improves metabolic disturbances in animal models of insulin 
resistance (Bergeron, Previs et al. 2001; Song, Fiedler et al. 2002; Pold, Jensen et al. 
2005). In skeletal muscle from rodents, AICAR enhances glucose transport and GLUT4 
translocation via insulin-independent pathway (Hayashi, Hirshman et al. 1998). Moreover, 
AICAR significantly increases glucose uptake in isolated human skeletal muscle strips 
from subjects with type 2 diabetes. This is associated with increased cell-surface content 
of GLUT4 (Koistinen, Galuska et al. 2003). Chronic treatment with AICAR leads to 
increased mitochondrial biogenesis in rat skeletal muscle (Winder, Holmes et al. 2000). 
Thus, AICAR, as an exercise mimetic, is an excellent research tool to study the effects of 
AMPK on glucose and lipid metabolism in metabolic disorders.  
  
Metformin 
Metformin is a commonly used antidiabetic agent that mainly acts as a suppressor of 
glucose production in liver. It also enhances glucose transport in skeletal muscle. A 
decade ago, it was shown that metformin activates the AMPK pathway in rat hepatocytes 
and abolishes lipogenic gene expression via reduced expression of SREBP-1c, a key 
lipogenic transcription factor (Zhou, Myers et al. 2001). In addition, AMPK activation by 
metformin in rat skeletal muscle leads to an increase in glucose transport (Zhou, Myers et 
al. 2001). Metformin has been shown to increase phosphorylation of AMPK also in 
skeletal muscle of type 2 diabetic subjects (Musi, Hirshman et al. 2002).   
 
 
 
 
31 
 
 
2.2.3.3 Natural activators 
Resveratrol 
Resveratrol (RSV), a natural polyphenol that is found in the skin of grapes and peanuts, 
has recently been shown to have antidiabetic properties. In vivo animal studies have 
reported a beneficial effect of RSV on weight loss, lipid and DAG accumulation in muscle 
(Um, Park et al. 2010). In addition, treatment with RSV increases mitochondrial 
biogenesis and physical endurance in rodents (Lagouge, Argmann et al. 2006; Um, Park et 
al. 2010). Although the compound has been discovered already a few decades ago, the 
mechanism of its action on metabolism is not yet clear. Resveratrol has been reported to 
increase the activity of SIRT1, a member of the sirtuin gene family, which shares 
homology with the yeast Sir2 protein (Howitz, Bitterman et al. 2003). Sirt1 is a 
histone/protein deacetylase that controls nicotinamide adenine dinucleotide (NAD+)- 
dependent deacetylation of target substrates, such as PGC-1α (Lagouge, Argmann et al. 
2006; Canto and Auwerx 2009). In addition to being involved in the regulation of 
processes like life span extension and apoptosis, Sirt1 may play an important role in 
glucose metabolism (Lagouge, Argmann et al. 2006; Canto and Auwerx 2009). Recent 
studies have proposed that resveratrol acts via direct activation of AMPK, which is well 
correlated with the stimulation of glucose uptake in rodent models (Breen, Sanli et al. 
2008; Canto, Jiang et al. 2010; Um, Park et al. 2010). In addition, the activation of SIRT1 
and deacetylation of PGC-1α by resveratrol may be dependent on AMPK activity (Canto, 
Jiang et al. 2010).  
 
2.3 Fatty acid-induced insulin resistance in skeletal muscle 
Elevated free fatty acid concentrations and reduced fatty acid oxidation in muscle are 
considered among the major causes of insulin resistance in obesity and type 2 diabetes. 
Several clinical studies have reported an association with elevated plasma FFA levels and 
impaired insulin sensitivity (Opie and Walfish 1963; McGarry 1992; Boden 2011). Acute 
elevation of FFA in plasma by lipid infusion leads to insulin resistance (Boden 2011), 
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whereas lowering chronically elevated plasma FFA levels improves insulin sensitivity in 
rodents and humans  (Ahren 2001; Qvigstad, Mostad et al. 2003). Several mechanisms 
have been suggested to explain how increased intramuscular fat may affect insulin 
sensitivity. One theory is that generation of active fatty acid-derived metabolites, such as 
diacylglycerol (DAG), long-chain fatty acyl-CoA:s and ceramides alter insulin action and 
consequently lead to defects in glucose utilization and insulin resistance (Bajaj, 
Suraamornkul et al. 2005; Holland, Brozinick et al. 2007; Kraegen and Cooney 2008). 
Another concept suggests low-grade chronic inflammatory state, induced by adipose-
tissue derived cytokines, negatively affects insulin signaling (Hotamisligil 2006). Recent 
studies have suggested endoplasmic reticulum (ER) stress as one of the major mechanisms 
involved in the free fatty acid- induced insulin resistance (Ozcan, Cao et al. 2004). Finally, 
an alternative theory based on the concept of mitochondrial overload and incomplete β-
oxidation has been proposed to explain the negative effects of free fatty acids in the 
pathogenesis of insulin resistance (Koves, Ussher et al. 2008). 
2.3.1 Intramuscular lipid metabolites 
The metabolic fate of free fatty acids depends on their composition and energy needs of 
the cell. Once entering the cell fatty acids are esterified into fatty acyl-CoA:s and at the 
next step they can either be directed to β-oxidation in the mitochondria or to glycerolipid 
synthesis such as formation of triacylglycerols (TG), diacylglycerols (DAG) or 
sphingolipids (Holland, Knotts et al. 2007). Increased fatty acid uptake in relation to the 
rate of β-oxidation, may lead to the accumulation of intramuscular active lipid 
metabolites, such as DAG:s, long-chain fatty acyl-CoA:s and ceramides, which negatively 
modulate insulin action (Holland, Knotts et al. 2007). The role of these lipid metabolites in 
insulin resistance is discussed below. 
2.3.1.1 Long chain fatty acyl-CoA:s 
Acyl-CoA esters of long chain fatty acids have been introduced as a marker of insulin 
resistance (Ellis, Poynten et al. 2000). High fat diet or lipid infusion increases the 
accumulation of long chain fatty acyl CoA:s in skeletal muscle of rats and humans, and 
this coincides with insulin resistance (Chalkley, Hettiarachchi et al. 1998; Ellis, Poynten et 
al. 2000). Moreover, pharmacological inhibition of lipolysis with acipimox significantly 
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improves whole-body glucose disposal with a parallel reduction of intramuscular long 
chain fatty acyl-CoA:s (Bajaj, Suraamornkul et al. 2005). The mechanism by which long 
chain fatty acyl-CoA:s interfere with insulin signaling remains unclear. It is possible that 
long chain fatty acyl-CoA:s may activate PKC isozymes (Yu, Chen et al. 2002). 
2.3.1.2 Ceramides 
Ceramides belong to the family of lipids and comprise the fundamental structure of all 
sphingolipid molecules. These are composed of two FA chains covalently linked to 
sphingosine. Previously it was assumed that ceramides are merely structural elements that 
make up sphingomyelin, a major lipid in the cell membrane bilayer. Nowadays, it is well-
established that ceramides act as signaling molecules and their synthesis is induced in 
response to stress stimuli (e.g., UV radiation, or inflammatory mediators) (Bikman and 
Summers 2011). There are two major pathways of ceramide synthesis – de novo synthesis 
from saturated long chain fatty acids such as palmitate, which is a complex biosynthetic 
pathway; and sphingomyelin hydrolysis, a process controlled by the enzyme 
sphingomyelinase (Bikman and Summers 2011) (Figure 3). 
In human skeletal muscle, the ceramide content is positively correlated with the fasting 
plasma FFA concentrations (Adams, Pratipanawatr et al. 2004). Increased ceramide 
accumulation was reported in skeletal muscle of insulin resistants rodents (Turinsky, 
O'Sullivan et al. 1990), in intralipid/heparin infusion-induced insulin resistance 
(Straczkowski, Kowalska et al. 2004), in obese insulin resistant humans (Adams, 
Pratipanawatr et al. 2004), as well as in lean offspring of type 2 diabetic patients 
(Straczkowski, Kowalska et al. 2007). Exposure to ceramide analogues alters the 
activation of AKT/PKB and as a consequence leads to defects in GLUT4 translocation and 
insulin-stimulated glucose uptake in muscle cells (Summers, Garza et al. 1998; Hajduch, 
Balendran et al. 2001). Ceramides promote the inhibition of AKT/PKB via activation of 
protein phosphatase 2 A (PP2A), which is the primary phosphatase responsible for the 
dephosphorylation of AKT/PKB. In addition, ceramides inhibit translocation of AKT/PKB 
from the cytoplasm to the plasma membrane (Bikman and Summers 2011). Myriocin is an 
inhibitor of the enzyme serine palmitoyl transferase (SPT), which regulates the initial rate-
limiting step of de novo ceramide synthetic pathway. Myriocin treatment lowers ceramide 
concentration in muscle and improves glucose tolerance and insulin action at the level of 
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AKT/PKB in rodent models of obesity and diabetes (Holland, Brozinick et al. 2007). 
Ceramides have also been linked to inflammatory response and activation of the toll-like 
receptor 4 (TLR4), which is an essential mediator in the synthesis and secretion of 
inflammatory cytokines (Bikman and Summers 2011). Recent data suggest that activation 
of TLR4 via its agonists such as LPS or saturated free fatty acids, increases ceramide 
production and transcription of genes encoding enzymes that are involved in de novo 
ceramide synthesis (Holland, Bikman et al. 2011).  
2.3.1.3 Diacylglycerol 
DAG is a lipid metabolite that plays an important role as a second messenger in 
intracellular signaling. DAG can be generated by esterification of two long chain fatty 
acyl-CoA:s to glycerol-3-phosphate or by breakdown of phospholipids by the enzyme 
phospholipase C or phosphatidylcholine by phospholipase D (Timmers, Schrauwen et al. 
2008). Increased DAG content has been reported in skeletal muscle of insulin resistant 
rodents (Heydrick, Ruderman et al. 1991; Avignon, Yamada et al. 1996) and humans 
(Itani, Ruderman et al. 2002), as well as in skeletal muscle following lipid infusion (Yu, 
Chen et al. 2002). In animal models, lipid infusion resulted in elevated levels of 
intracellular DAG, which was associated with the activation of PKCθ, which is known to 
inhibit insulin signaling via serine phosphorylation of the IRS-1(Itani, Ruderman et al. 
2002; Yu, Chen et al. 2002). The accumulation of DAG has also been positively correlated 
with increased activity of PKCθ in skeletal muscle of obese humans (Itani, Ruderman et 
al. 2002).  
It has been hypothesised that an increase in fatty acid oxidation can lower the level of 
intramuscular lipid metabolites and thus protect the cells from fatty acid-induced insulin 
resistance. In L6 muscle cells, overexpresion of CPT-1 protects the cells from palmitate- 
induced insulin resistance by reducing DAG and ceramide levels with a concommitant 
decrease in the activation of PKCθ (Sebastian, Herrero et al. 2007).  
2.3.2 Mitochondrial β-oxidation of fatty acids  
A few decades ago, Randle et al introduced a link between muscle glucose and lipid 
metabolism. They postulated that when β-oxidation of fatty acids is increased glucose 
oxidation is decreased, a phenomenon that is called “Randle Cycle” (Randle, Garland et 
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al. 1963). The existence of the Randle Cycle would suggest that substrate preference 
contributes to the development of insulin resistance. However, as mentioned above, 
enhancing β-oxidation of fatty acids has been proposed as a protective mechanism to 
combat insulin resistance. Additionally, a number of studies have shown that insulin 
resistant subjects have a decrease in fatty acid oxidation capacity and an impaired 
mitochondrial function (Sebastian, Herrero et al. 2007; Schenk, Saberi et al. 2008). Taken 
together, free fatty acids may affect insulin stimulated glucose transport by a mechanism 
different to the one proposed by Randle. Recent observations in skeletal muscle have 
introduced a new intresting concept, which is based on the incomplete β-oxidation and an 
increase in fatty acid oxidation in insulin resistant states. 
 Mitochondrial β-oxidation 
Before long chain fatty acyl-CoA:s undergo β-oxidation, they must be transported across 
the mitochondrial outer and inner membranes, as they cannot diffuse freely without a 
transporter molecule. Transport is facilitated by a carnitine-dependent transport system, 
which consists of carnitine palmitoyl transferase-1 (CPT-1), carnitine translocase (CT), 
and carnitine palmitoyl transferase-2 (CPT-2). CPT-1 is the key and rate-limiting enzyme 
that catalyses the reaction where long chain fatty acyl-CoA is covalently bound to 
carnitine and forms an acylcarnitine. Acylcarnitine is then transported into the 
mitochondria by CT. Once in the mitochondrial matrix, acylcarnitine is converted back to 
long chain fatty acid and carnitine by CPT-2 (Mingrone 2004). Subsequently, the long 
chain fatty acyl-CoA enters the β-oxidation cycle, where the length of the molecule is 
reduced by two carbons per cycle producing acetyl-CoA, NADH and FADH2. The acetyl-
CoA molecules are the end products of β-oxidation and enter the TCA cycle, which 
produces NADH and FADH2. NADH and FADH2 are then used to produce ATP in the 
electron transport chain (ETC) (Berg, Tymoczko et al. 2007). If acetyl-CoA molecules do 
not enter the TCA cycle, they are synthetised into acylcarnitines by the enzyme carnitine 
acetyl transferase (CAT), which is located inside the mitochondria (Adams, Hoppel et al. 
2009).
 
 
 
 
36 
 
Figure 3. Schematic representation of the two major pathways involved in the ceramide 
synthesis. 
 
 
2.3.2.1 Incomplete β- oxidation  
The novel concept of incomplete β- oxidation suggests that lipid oversupply promotes β-
oxidation by activation of peroxisome proliferator-activated receptor (PPAR) genes and by 
increased substrate supply, but without activation of TCA cycle and ETC. This results in 
the failure of the muscle to completely oxidize fatty acids resulting in an accumulation of 
acid soluble metabolites (ASM), such as acylcarnitines (Koves, Ussher et al. 2008). This 
hypothesis is supported by animal studies where the markers of incomplete β-oxidation 
accumulate in insulin resistant muscle. Conversely, reduction of the products of 
incomplete β-oxidation improves insulin sensitivity (Koves, Ussher et al. 2008). Elevated 
plasma acylcarnitine concentrations have been reported in type 2 diabetic patients 
compared to non-diabetic people (Adams, Hoppel et al. 2009). In addition, increased 
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levels of urinary acylcarnitines have been observed in type 2 diabetic subjects, which 
supports the existence of incomplete β-oxidation in insulin resistance (Moder, Kiessling et 
al. 2003).  
 
The mechanism by which incomplete β-oxidation affects insulin signaling and leads to 
insulin resistance is unknown. Acylcarnitines may alter the function of the mitochondrial 
proteins by acylation and acetylation  (Kim, Sprung et al. 2006; Muoio and Koves 2007). 
Additionally, incomplete β-oxidation can lead to the formation of reactive oxygen species 
(ROS), which can lead to the formation of lipid peroxides and damage of the 
mitochondrial enzymes and DNA (Andreyev, Kushnareva et al. 2005). Moreover, ROS 
are know to activate inflammatory proteins, such as JNK and IKKβ (Bloch-Damti and 
Bashan 2005).  
2.3.3 Inflammation 
Obesity and insulin resistance are inflammatory states, characterized by increased 
production of proinflammatory cytokines and activation of inflammatory signaling 
pathways (Hotamisligil 2006). Adipose tissue is an important initiator of the inflammatory 
response. In addition to its role in storage of energy as fat, it is well established that 
adipose tissue also functions as an endocrine and paracrine organ. A variety of cytokines 
and chemokines, such as tumour necrosis factor-α (TNF-α), IL-6 or monocyte chemotactic 
protein 1 (MCP-1) are secreted in abundance from obese insulin-resistant subjects 
(Goossens 2008). Thus, adipose tissue may affect inflammatory signaling and insulin 
resistance in skeletal muscle via circulating cytokines. In addition, plasma FA levels 
derived from excess adipose tissue can activate inflammatory responses and affect insulin 
sensitivity by the accumulation of lipids or via activation of Toll-like receptors.  
2.3.3.1 Toll-like receptors 
Toll-like receptors (TLR) play an essential role in the activation of inflammatory signaling 
associated with innate immunity. Recently, it has been suggested that TLR2 and TLR4 
receptors are involved in skeletal muscle insulin resistance. TLR4 is the best-described 
TLR and known target for saturated fatty acids and LPS. In TLR4-knockout mice infusion 
of lipids does not induce insulin resistance in skeletal muscle in comparison to wild type 
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mice, suggesting an important role of TLR4 in acute lipid-induced insulin resistance (Shi, 
Kokoeva et al. 2006). Moreover, a loss-of-function mutation in TLR4 protects mice 
against development of diet-induced insulin resistance (Tsukumo, Carvalho-Filho et al. 
2007). In isolated intact soleus muscle from these animals, exposure to palmitate does not 
affect insulin signaling, glucose uptake or glycogen synthesis. TLR4 is also involved in 
ceramide biosynthesis (Holland, Bikman et al. 2011). The data regarding TLR2 are sparse 
and the role of TLR2 in insulin resistance is less known. It has been demonstrated that 
blocking the activity of TLR2 in C2C12 muscle cell line protects these cells against 
palmitate induced insulin resistance (Senn 2006). Thus, both TLR2 and –4 appear to 
contribute to lipid-induced insulin resistance. 
2.3.3.2 Macrophages 
Obese adipose tissue is infiltrated with an increased number of macrophages. These cells 
are the source of proinflammatory cytokine secretion that may cause insulin resistance 
(Olefsky and Glass 2010). Adipose tissue macrophage infiltration is positively correlated 
with body mass index, adipocyte size and insulin resistant state (Goossens 2008). Recent 
studies have shown the presence of macrophages also in skeletal muscle. Increased 
macrophage content has been reported in skeletal muscle from obese mice (Weisberg, 
McCann et al. 2003), as well as in HFD fed mice (Nguyen, Favelyukis et al. 2007).  
Increased macrophage infiltration has also been observed in vastus lateralis biopsies from 
obese humans (Varma, Yao-Borengasser et al. 2009). Co-culture of human myotubes with 
macrophages in the presence of palmitic acid results in impairments in insulin signaling at 
the level of AKT and increased activation of JNK and IκBα (Varma, Yao-Borengasser et 
al. 2009). IKK-β deletion of myeloid cells in mice on HFD improves skeletal muscle and 
whole body insulin resistance (Arkan, Hevener et al. 2005). Collectively, these studies 
provide evidence that cytokines derived from macrophages either in adipose tissue or 
skeletal muscle may contribute to the skeletal muscle insulin resistance.  
2.3.3.3 Stress Kinases 
Activation of cytokine receptors, intracellular lipid accumulation and activation of TLRs 
lead to activation of stress kinases, such as c-Jun N-terminal kinase (JNK), inhibitor of 
NF-κB kinase (IKK) and protein kinase C (PKC), which are central mediators of insulin 
resistance.  
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NF-κB pathway 
In the basal state NF-κB is bound to its inhibitory protein IκBα in the cytoplasm. IKKβ 
phosphorylates IκBα, which subsequently targets IκBα to proteosomal degradation. This 
results in nuclear translocation of NFκB and transcriptional activation of several 
proinflammatory genes. In human skeletal muscle, fatty acid-induced insulin resistance is 
closely associated with DAG accumulation and reduction of IκBα (Itani, Ruderman et al. 
2002). Acute hyperlipidemia and HFD have also been reported to decrease IκBα levels in 
rodent skeletal muscle (Bhatt, Dube et al. 2006). Targetting the IKKβ/NFκB signaling 
pathway with high doses of salicylate, an inhibitor of IKKβ, prevents insulin resistance in 
skeletal muscle from rodents (Kim, Kim et al. 2001) and humans (Kim, Kim et al. 2001). 
IKKβ has also been shown to negatively affect insulin signaling by directly 
phosphorylating IRS-1 at serine residues (Gao, Hwang et al. 2002). On the other hand, 
muscle specific IKKβ knockdown mice are not protected against diet-induced insulin 
resistance (Rohl, Pasparakis et al. 2004). Pharmacological or genetic modification of 
NFκB does not protect C2C12 myotubes from insulin resistance induced by palmitate 
(Hommelberg, Plat et al. 2011). The pharmacological approaches, such as treatment with 
salicylate may actually be IKK-independent. It is known that salicylate is able to inhibit 
serine kinases, such as JNK and S6K, which interfere with insulin signaling through IRS-1 
phosphorylation (Gao, Zuberi et al. 2003). Therefore, IKKβ/NFκB pathway may not play 
a central role in FFA-induced insulin resistance in skeletal muscle.  
 
JNK 
JNK activity is significantly increased in insulin resistant skeletal muscle of obese rats and 
humans (Hirosumi, Tuncman et al. 2002; Bandyopadhyay, Yu et al. 2005; Todd, Watt et 
al. 2007). Moreover, when challenged with HFD, mice with muscle specific JNK-1 
deficiency are protected from serine phosphorylation of IRS-1 and muscle insulin 
resistance (Sabio, Kennedy et al. 2010). The palmitate-induced insulin resistance is also 
diminished in JNK-depleted C2C12 muscle cells (Vijayvargia, Mann et al. 2010).  Taken 
together, JNK activity plays an important role in obesity and diabetes and its inhibition 
may be a potential target to treat insulin resistance in humans.  
 
 
 
 
40 
 
PKC 
Conventional (c) and novel (n) PKC:s have a negative impact on the insulin signaling 
pathway. These serine kinases can be activated by DAG and they induce insulin resistance 
by phosphorylating defined residues of IRS-1 (Yu, Chen et al. 2002; Ragheb, Shanab et al. 
2009).  Among the several isoforms of novel/conventional PKCs, the PKCθ and PKCε are 
mainly associated with DAG-induced skeletal muscle insulin resistance in rodents and 
humans (Idris, Gray et al. 2001; Samuel, Petersen et al. 2010). Moreover, PKCθ knockout 
mice are prevented from muscle insulin resistance during lipid infusion (Kim, Fillmore et 
al. 2004). Increasing DAG content via inhibition of diacylglycerol kinase δ (DGKδ) 
results in activation of n/c PKCs and increases phosphorylation of IRS-1 at Ser307 in intact 
skeletal muscle from rat (Chibalin, Leng et al. 2008). Besides direct inhibitory 
phosphorylation of IRS-1, PKCs can act upstream of the stress kinases JNK and IKKβ and 
thereby influence insulin signaling by serine phosphorylation of IRS-1. PKCε has also 
been shown to interfere with insulin signaling by directly associating with and inhibiting 
the tyrosine kinase activity of the insulin receptor in skeletal muscle of diabetic animals 
(Ikeda, Olsen et al. 2001). Finally, PKCζ has been shown to mediate ceramide-induced 
insulin resistance, as discussed in section 2.3.1.2.  
2.3.4 Endoplasmic reticulum stress 
The ER stress response has strongly been implicated in obesity and the pathogenesis of 
diabetes. ER stress affects insulin action in liver and adipose tissue as well as the function 
and mass of the pancreatic beta cells (for review (Hotamisligil 2010; Cnop, Foufelle et al. 
2012)). The role of ER stress in skeletal muscle in fatty acid-induced insulin resistance is 
controversial and is discussed in more detail below. 
2.3.4.1 UPR pathway 
ER is an intracellular organelle and the principal site of protein folding and 
posttranslational modification, lipid synthesis and calcium storage. Under conditions such 
as high intracellular lipids, glucose deprivation or calcium imbalance, ER homeostasis is 
disturbed and thus the organelle has developed an adaptive response system known as the 
unfolded protein response (UPR) (Hotamisligil 2010). The canonical UPR pathway 
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consist of three different mediators: inositol requiring enzyme-1 (IRE1), PKR-like 
endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6) that 
work to restore ER homeostasis (Figure 4). In “stress-free” cell, these three proteins are 
bound to the chaperone-binding protein/glucose-regulated protein 78 (BiP/GRP78) and 
remain inactive. Accumulation of misfolded proteins leads to the activation of these three 
signaling arms by the dissociation of their proximal effectors from BiP (Bertolotti, Zhang 
et al. 2000; Shen, Chen et al. 2002). Activation of PERK and IRE1 occurs via 
transautophosphorylation, whereas the activation of ATF6 into an active transcription 
factor occurs by cleavage in the Golgi apparatus by two proteases: serine protease site-1 
(S1P) and the metalloprotease site-2 (S2P) (Chen, Shen et al. 2002; Flamment, Kammoun 
et al. 2010). Active PERK phosphorylates the eukaryotic translation initiation factor 2 
(eIF2α) at Ser 51 leading to the suppression of global protein translation (Harding, Zhang 
et al. 1999). Moreover, phosphorylation of eIF2α induces downstream translation of 
ATF4, which controls the gene expression of the CCAAT/enhancer binding protein 
homologous protein (CHOP) (Ma, Brewer et al. 2002). However, eIF2α can also be 
phosphorylated by other kinases like the double-stranded RNA-activated protein kinase 
(PKR) and the general control non-derepressible kinase 2 (GCN2). The role of these 
kinases in ER stress is unclear and thus eIF2α phosphorylation status alone cannot be used 
to confirm the presence or absence of ER stress (Ron and Walter 2007). The release of 
IRE1 from the BiP complex results in the activation of the endonuclease activity of IRE1 
and results in splicing of the transcription factor X-box binding protein-1 (XBP-1) 
(Sidrauski and Walter 1997). The spliced form of XBP-1 (XBP-1s) regulates 
independently or in co-operation with ATF6 the production of chaperone proteins 
(including BiP), ER-associated protein degradation (ERAD) and phospholipid synthesis, 
to improve the folding capacity of ER and to alleviate the ER stress (Lee, Iwakoshi et al. 
2003).  
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Figure 4. UPR pathway and its crosstalk with insulin signaling. 
  
2.3.4.2 UPR pathway and the link to insulin signaling 
ER stress and activation of the UPR have been linked to the insulin signaling pathway. 
First, XBP-1 deficiency leads to the development of insulin resistance and type 2 diabetes 
in mice on HFD (Ozcan, Cao et al. 2004). In addition, the activation of the IRE-1 arm 
inhibits insulin action via the activation of JNK, which phosphorylates IRS-1 at specific 
inhibitory serine residues. Recently, two independent studies demonstrated that XBP-1s 
interacts with the p85 regulatory subunit of PI3K and that this association facilitates the 
nuclear translocation of XBP-1s and induction of the UPR target genes (Park, Zhou et al. 
2010; Winnay, Boucher et al. 2010). Park et al. demonstrated that in the liver of ob/ob 
mice on HFD, this interaction is diminished and thereby the animals cannot cope with ER 
stress. Moreover, overexpression of the p85 subunit in liver of these mice restores XBP-1s 
translocation to the nucleus, enhances transcription of XBP-1s– regulated genes, and most 
 
 
 
 
43 
importantly, improves glucose tolerance (Park, Zhou et al. 2010). Although this novel 
insulin regulated pathway may provide new approaches to treat diabetes and insulin 
resistance, further studies on p85-XBP1s interaction are required to validate this 
interaction in clinical context as well as in extrahepatic tissues.  
2.3.4.3 ER stress in skeletal muscle 
The link between ER stress and insulin resistance in skeletal muscle is less understood. 
Presently, only a few studies have reported the presence of ER stress in skeletal muscle of 
obese and type 2 diabetic animal models. In mice, ER stress markers are elevated after 6 
and 20 weeks of HFD (Deldicque, Cani et al. 2010). Palmitic acid has been shown to 
induce ER stress in C2C12 and L6 muscle cells (Peng, Li et al. 2011; Hage Hassan, 
Hainault et al. 2012; Rieusset, Chauvin et al. 2012). However, the mechanism of ER stress 
and its effect on insulin sensitivity has been divergent in these studies. Peng et al. have 
demonstrated that treatment with 4-phenyl butyric acid (4-PBA), a chemical chaperone, 
alleviates palmitate-induced ER stress in C2C12 and L6 cell lines and improves insulin 
signaling and glucose uptake. Interestingly, the addition of oleate to the medium has a 
similar effect as 4-PBA and protects the cells from palmitate-induced ER stress and 
insulin resistance.  On the other hand, in two other studies the prevention of palmitate-
induced ER stress with the chemical chaperones 4-PBA or tauroursodeoxycholic acid 
(TUDCA), a taurine-conjucated derivative of bile acids, does not prevent palmitate-
induced insulin resistance. In addition, although overexpression of the chaperon protein 
BiP reduces ER stress in C2C12 cells, this does not improve reduced insulin action 
induced by palmitate (Rieusset, Chauvin et al. 2012). When muscle cells are treated with 
tunicamycin (an inhibitor of protein glycosylation that induces ER stress) and with 
chemical chaperones, the gene expression of the UPR pathway is decreased. The negative 
effect of tunicamycin on insulin action is also prevented (Rieusset, Chauvin et al. 2012).  
Similar effect of chaperones is also seen on glucosamine (GlcN)-induced insulin 
resistance (Raciti, Iadicicco et al. 2010).  
 
Less is known about the presence of ER stress in insulin resistant human skeletal muscle. 
Induction of ER stress has been observed in human primary myotubes treated with 
palmitate (Peter, Weigert et al. 2009). In human in vivo studies, treatment with the 
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chemical chaperone TUDCA for one month increases insulin sensitivity in liver and 
muscle of obese men by approximately 30 % in comparison to the placebo group. 
However, in this study the impairment in insulin signaling does not coincide with changes 
in ER stress markers in skeletal muscle (Kars, Yang et al. 2010).  Moreover, six weeks of 
HFD resulted in small increases in blood glucose during oral glucose tolerance test, but 
not in the activation of ER stress in skeletal muscle from physically active lean men 
(Deldicque, Van Proeyen et al. 2011).  
 
Taken together, there may be a dissociation between palmitiate-induced ER stress and 
insulin resistance. ER stress plays an important role in glucosamine-induced insulin 
resistance, whereas palmitate may impair insulin action via mechanisms different from ER 
stress signaling. 
2.3.4.4 ER stress and exercise 
Skeletal muscle possess smooth ER called sarcoplasmic reticulum (SR), which is highly 
specialized to maintain calcium concentration and has a minor role in protein secretion. 
Thus, SR plays an important role in the regulation of muscle contraction. It has been 
hypothesised that skeletal muscle adapts to exercise training via activation of the UPR 
pathway that protects from further stress. Indeed, acute exercise activated ER stress 
markers in skeletal muscle from mice. Moreover, a 4-week training activated a different 
pattern of UPR markers in comparison to sedentary mice, who are trained only once (Wu, 
Ruas et al. 2011). PGC-1α has been shown to regulate UPR pathway in response to 
exercise through coactivation with ATF6 (Wu, Ruas et al. 2011). ER stress has also been 
shown to be activated in human skeletal muscle after a 200 km run. This is accompanied 
with a reduced activity of the proteasome, which suggests compensatory mechanisms to 
protect against cellular stress (Kim, Jamart et al. 2011).   
2.4 Insulin resistance in other tissues 
In addition to skeletal muscle, liver and adipose tissue are additional main targets of 
insulin action and insulin resistance in these organs accounts for the core defects in type 2 
diabetes. Moreover, β-cell failure plays an important role in the progression of the 
pathophysiological events leading to T2DM. Thus, deep understanding of the contribution 
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of these organs to whole body insulin resistance and the cross-talk between these tissues is 
essential in attempts to prevent the development of T2DM and to effectively control 
metabolic balance in diabetic patients. 
2.4.1 Liver 
Liver is one of the major secretory organs and has a pivotal role in carbohydrate and lipid 
metabolism. Increased glucose production due to enhanced gluconeogenesis and 
glycogenolysis is a metabolic hallmark of insulin resistance in type 2 diabetes mellitus 
(Consoli, Nurjhan et al. 1990; Magnusson, Rothman et al. 1992). After an overnight fast, 
the liver of healthy individuals produces glucose at the rate of ~2 mg/ kg per min, whereas 
in diabetic state the production is increased up to ~2.5 mg/kg per min. Moreover, the 
insulin-induced suppression of hepatic glucose production is impaired in Type 2 diabetes. 
Increased hepatic glucose production in T2DM is in good correlation with the increased 
fasting plasma glucose and fasting plasma insulin levels, and accounts for fasting 
hyperglycaemia (DeFronzo, Ferrannini et al. 1989; Defronzo 2009). Increased hepatic 
glucose production in T2DM is also related to increased circulating glucagon levels and 
hepatic sensitivity to glucagon, lipotoxicity as well as glucose toxicity  (Defronzo 2009).  
Liver is the main site of de novo lipogenesis, which allows the synthesis of fatty acids 
from excess carbohydrates in the diet. Newly synthesized fatty acids are esterified to 
triacylglycerols that can later be secreted as lipoproteins such as VLDL. In physiological 
conditions, there are also other sources of fatty acids that can be delivered for TG 
synthesis in the liver. Among them the most important are non-esterified fatty acids 
originating from the hydrolysis of TGs stored in adipose tissue. Imbalances in the rate of 
fatty acid uptake and oxidation in the liver, hepatic de novo fatty acid synthesis, and 
secretion of TG lead to ectopic lipid accumulation and insulin resistance in the liver 
(Fabbrini, Sullivan et al. 2010). Recent evidence suggests that skeletal muscle insulin 
resistance may be an early event responsible for eventual non-alcoholic fatty liver disease, 
a predictor of metabolic syndrome and T2DM. Studies using magnetic resonance 
spectroscopy have revealed that glycogen synthesis in skeletal muscle is decreased, 
whereas hepatic de novo lipogenesis is increased after a carbohydrate meal in young 
insulin resistant individuals. This results in an increase in liver triglyceride synthesis and 
increased plasma triglyceride concentration (Petersen, Dufour et al. 2007). Importantly, 
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one bout of acute exercise increases postprandial glycogen synthesis in skeletal muscle 
and decreases hepatic triglyceride synthesis (Rabol, Petersen et al. 2011). Thus, insulin 
resistance in skeletal muscle is an early target to treat and prevent the development of non-
alcoholic fatty liver disease.    
2.4.2 Adipose tissue  
The main function of the adipose tissue is to store excess energy in the form of TG. 
During energy deprivation fat stored as TG undergoes lipolysis. Free fatty acids (FFA) are 
then delivered to other tissues for energy production. Insulin is the main regulator of fatty 
acid metabolism in adipose tissue, and insulin promotes fat storage by its antilipolytic 
effect as well as by enhancing synthesis of TG:s. Adipose tissue is composed not only of 
adipocytes (70 % of total mass) but also of stromal vascular fraction that contains immune 
cells such as macrophages.  Macrophages have a pivotal role in inflammatory responses 
(Bays, Gonzalez-Campoy et al. 2008).  
In T2DM, metabolic defects in adipose tissue can impact other tissues such as skeletal 
muscle and liver via different mechanisms (Bays, Gonzalez-Campoy et al. 2008). First, 
adipocytes are resistant to the antilipolytic effect of insulin, and studies using insulin 
clamp technique have shown that lean type 2 diabetic and obese nondiabetic patients have 
impaired antilipolytic effect of insulin (Groop, Bonadonna et al. 1989). This leads to an 
elevation in plasma FFA concentrations, which may induce insulin resistance in other 
tissues (Opie and Walfish 1963; Boden 2011). Moreover, adipose tissue secretes a large 
number of different hormones, cytokines, chemokines and other peptides that influence 
insulin action in an autocrine, paracrine and endocrine fashion. In obesity adipose tissue 
macrophage content is increased. Inflamed adipose tissue has been suggested to contribute 
to insulin resistance in other tissues such as skeletal muscle and liver by increased 
secretion of several cytokines and proinflammatory mediators, such as TNF-α, IL-6 or 
MPC-1. These cytokines also contribute to increased lipolysis (Hotamisligil 2006; Bays, 
Gonzalez-Campoy et al. 2008). Adipose tissue also secretes adiponectin, an insulin 
sensitizing adipokine. In insulin resistance, adiponectin secretion is markedly 
compromised (Bays, Gonzalez-Campoy et al. 2008). Finally, in insulin resistance 
adipocytes have a decreased capacity to store fat. Taken together, these aspects enable an 
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overflow of fatty acids to other tissues such as liver and skeletal muscle, and contribute to 
development of insulin resistance (Bays, Gonzalez-Campoy et al. 2008).  
2.4.3 The effect of insulin resistance on β-cell failure 
Although insulin resistance plays an important role in the pathogenesis of T2DM, β-cell 
failure is also essential factor and responsible for the progression of impaired glucose 
tolerance (IGT) to T2DM. Multiple factors including age, genetic factors, and acquired 
factors like glucotoxicity, lipotoxicity and insulin resistance contribute to β-cell failure 
(DeFronzo and Abdul-Ghani 2011). Initially, plasma insulin concentrations are increased 
in the insulin resistance state, which is viewed as a compensatory mechanism. However, 
as β-cell failure progesses, first phase insulin secretion is blunted and β-cell mass 
decreases. It is estimated that 50% of the β-cells are already lost at the detection of 
hyperglycaemia. Finally, there may be a further deterioration of insulin secretion in T2DM 
which leads to a need for insulin-based therapy, as in T1DM. Early prevention of 
development of T2DM should protect against the loss of β-cells mass and function. 
Weight gain and physical inactivity lead to insulin resistance and create pressure for β-
cells to hypersecrete insulin. This plays a role in progressive β-cell failure. Intrestingly, 
exercise and weight loss can improve insulin sensitivity and glucose tolerance as well as 
augment insulin secretion (Henry, Wallace et al. 1986; Koivisto, Yki-Jarvinen et al. 1986; 
Kitabchi, Temprosa et al. 2005). In addition, treatment with TZDs, but surprisingly not 
with metformin, can also preserve β-cell function besides their effect on insulin sensitivity 
(DeFronzo and Abdul-Ghani 2011). Thus, the ideal intervention to prevent development 
of T2DM and to improve glycaemic control in established diabetes would impact insulin 
sensitivity and protect against the loss of β-cell mass and function. 
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3 Aims of the study 
The specific aims of the study are: 
1. To study if globular adiponectin (gACRP) impacts glucose transport in type 2 
diabetic human skeletal muscle (study I). 
2. To study the effect of rosiglitazone on glucose transport and metabolic signaling in 
human skeletal muscle (study II) 
3. To study acute metabolic effects of the polyphenol resveratrol, and to examine if 
resveratrol could combat palmitate-induced insulin resistance in human skeletal 
muscle (study III). 
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4 Methods 
 
The methods used in this thesis are described briefly below. A more detailed description 
of the methods can be found in the individual publications, which are marked with the 
Roman numerals. 
 
4.1 Subjects 
The clinical characteristics of the subjects are presented in Table I.  
 
Study group No. of 
subjects 
Age 
BMI 
(kg/m2) 
Fasting 
glucose 
(mmol/l) 
2h glucose 
(mmol/l) 
Study I 
Nondiabetic 
men 
15 59±1 28±1 5.6±0.1 5.4±0.4 
Type 2 
diabetic men 
12 56±1 30.5±1.1 6.7±0.3 ND 
Study II 
Healthy men 15 50±3 26.9±1.1 5.3±0.1 5.3±0.4 
Study III  
Healthy men 6 54±3 25±1.7 5.5±0.1  5.3±0.5 
 
Table 1. Subject characteristics. Glucose concentration was determined from whole blood 
(I,II) or from plasma (III). The volunteers were recruited separately for each study.  
4.2 Open muscle biopsy (Studies I-III) 
A muscle biopsy was taken surgically from vastus lateralis muscle under local anesthesia. 
Muscle was placed in oxygenated Krebs-Henseleit buffer (KHB). Smaller muscle strips 
(25 mg) were dissected, mounted on Plexiglass clamps, and incubated for 60-240 min at 
35°C in KHB under basal conditions with or without palmitate, or with or without insulin, 
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or were exposed to gACRP, AICAR or rosiglitazone (Koistinen, Galuska et al. 2003). 
4.3 Human primary muscle cells (study III) 
A skeletal muscle biopsy was trypsin digested to isolate satellite cells. These were grown 
to 80% confluent myoblasts in the proliferating medium (Dulbecco’s modified Eagle 
Medium: Nutrient Mixture F–12 (DMEM/F12) medium supplemented with 20 % foetal 
bovine serum (FBS), 1% penicillin, 1% streptomycin, 1% Fungizone). Subsequently, 
myoblast were purified using magnetic cell separation with CD56 antibody. 
Differentiation of the myoblast was started by switching proliferating medium to 
differentiation medium (DMEM/F12 containing 2% FBS, 1% penicillin, 1% streptomycin, 
1% Fungizone). The myotubes differentiated for 7 days were serum-starved for 2 h before 
each experiment in low glucose-DMEM supplemented with 0.5 % FFA free BSA (Al-
Khalili, Kramer et al. 2004). 
4.4 Immunocytochemistry (study III) 
To assess the formation and purity of myotubes immunocytochemistry was used for the 
visualisation of myogenin expresion. Briefly, myoblast were proliferated on glass 
coverslips until they reached 80 % confluence and subsequently differentiation was started 
The samples for the visualisation of myogenin were collected between 0-7 days. The 
pictures were taken using AXIOVERT 200M microscope (Carl Zeiss AG, Germany). 
4.5 L6 cell line (study III) 
L6 myoblasts were obtained from American Type Culture Collection (ATCC). The cells 
were proliferating in DMEM medium supplemented with 10 % FBS, 1% penicillin, 1% 
streptomycin, and 1% Fungizone. At 80% confluence medium was switched to 
differentiation medium (DMEM, 2 % horse serum (HS)).  All experiments were 
performed using L6 myotubes differentiated for 7 days with 2 h starvation in low-glucose 
DMEM supplemented with 0.5 % FFA-free BSA prior to the experiment. 
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4.6 Metabolic assays of intact muscle strips 
4.6.1 Glucose transport (studies I,II) 
Muscle strips were incubated in Krebs-Henseleit buffer supplemented with 5 mM glucose 
and 0.1 % BSA or 4% FFA-free BSA depending on the study protocol. Intact skeletal 
muscle strips were rinsed for 10 min in KHB containing 20 mM mannitol and 0.1 % BSA 
or 4 % FFA-free BSA. For the last 20 min, muscle strips were transferred to KHB buffer 
supplemented 5 mM 3-0-methyl [3H] glucose (800 µCi/mmol) and 15 mM [14C] mannitol 
(53 µCi/mmol). Glucose transport was analyzed by measuring the accumulation of 
intracellular of 3-0-methyl [3H] glucose in the scintillation counter (Koistinen, Galuska et 
al. 2003; Glund, Deshmukh et al. 2007). 
4.6.2 Glycogen synthesis  
Human skeletal muscle strips were incubated in KHB (containing 4 % FFA free BSA and 
5 mM glucose) with or without 1 mM palmitate and with or without 1.2 nM insulin for 4 
h. Thereafter, muscles were transferred to KHB supplemented with 5 mM [14C]-glucose 
(0.3 µCi/mmol) for 1 h to assess glucose incorporation rate into glycogen. Muscles were 
frozen in liquid nitrogen and stored at -80oC. Glucose incorporation into glycogen was 
analyzed by precipitation of glycogen and measuring radioactivity by liquid scintillation 
counting (Glund, Deshmukh et al. 2007). 
4.7 Metabolic assays in cell cultures (study III) 
4.7.1 Glucose uptake  
Human primary myotubes were pre-exposed to resveratrol (RSV) or other compounds for 
4 h, followed by incubation with or without 100 nM insulin for 1 hour. Subsequently, the 
cells were incubated in zero-glucose DMEM (0.5 % FFA free BSA, 10 µM 2-Deoxy-
Glucose, [3H]-2-Deoxy-D-Glucose (100 mCi/mmol) for 15 min to assess glucose uptake. 
The concentrations of RSV and other compounds were maintained unchanged until the 
end of the experiment. The radioactivity was measured in the β-counter (Al-Khalili, 
Bouzakri et al. 2006). 
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4.7.2 Glycogen synthesis 
After 4 h pre-exposure to compounds of interest, the cells were stimulated with insulin 
(100 nM) for 2 h and labeled D-[U-14C]-glucose (1µCi/ml; final specific activity 0.18 
µCi/µl) was added for the last 90 min. The glycogen was precipitated and the glucose 
incorporation into glycogen was determined by measuring radioactivity by liquid 
scintillation counting (Al-Khalili, Bouzakri et al. 2006). 
4.7.3 Palmitate oxidation 
The cells were exposed to RSV or other compounds of interest for 4 h with the addition of 
[9,10-3H]-palmitic acid (5 µCi/ml of medium). The 3H labeled water was extracted from 
the incubation medium with charcoal. The radioactivity of the samples was determined by 
scintillation counting (Salehzadeh, Rune et al. 2011). 
 
4.8 Western blotting (studies I-III) 
4.8.1 Tissue processing (studies I,II) 
Human muscle strips were homogenized in ice-cold buffer (20 mM Tris (pH 7.8), 137 
mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% Triton X-100, 10 % (w/v) glycerol, 10 mM 
NaF, 0.5 mM Na3VO4, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 0.2 mM PMSF, 1 mM DTT, 
1 mM EDTA). The samples were put on rotor for 60 min at +4 oC and centrifuged for 10 
min (12 000 g, +4 oC). Protein concentration was determined with BCA kit. Muscle 
extracts were mixed with Laemmli buffer and heated (56 oC) for 20 min. Samples (30 µg) 
were separated by SDS-PAGE (6-12 %). Proteins were transferred to PVDF membranes 
and blocked in 5 % or 7.5 % milk or 5 % BSA.  Membranes were incubated with primary 
antibodies. Thereafter, membranes were incubated with secondary HRP-conjugated 
antibodies. Immunoreactive proteins were detected by enhanced chemiluminescence (ECL 
plus) and quantified by densitometry using the ImageJ software. 
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4.8.2 Cell lysates (study III) 
Human primary myotubes or L6 myotubes were washed and extracted in ice-cold lysing 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5 mM Na3VO4, 1 µg/ml leupeptin, 
1 µg/ml aprotinin, 0.2 mM PMSF). The samples were centrifuged (12 000 g) at +4 oC for 
10 min. Protein concentration was determined with BCA kit. The supernatant was 
resuspended in Laemmli Buffer and the protein samples were heated for 20 min at 56 oC. 
The proteins (20 µg) were separated by SDS-PAGE, followed by transfer to the PVDF 
membrane. Membranes were blocked in 5 % milk or 5% BSA and incubated with primary 
antibodies. Next, membranes were washed and incubated with secondary antibodies for 1 
hour at room temperature. The proteins were detected using enhanced chemiluminescence 
and quantified by densitometry using the ImigeJ Software. 
 4.8.3 Immunoprecipitation (study III) 
Human primary myotubes were lysed in ice-cold IP lysing buffer (50 mM Tris pH 7.5, 
150 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycholate) and lysates were pre-cleaned 
with Protein A-Agarose and Protein G-Agarose. Anti-PGC-1α antibody was added and the 
lysates were incubated overnight. Next, Protein-A agarose beads were added and 
incubated for 4 h. The agarose-immunocomplex was washed with IP washing buffer (50 
mM Tris pH 7.5, 250 mM NaCl, 0.1 % NP-40, 0.05 % sodium deoxycholate). The pellet 
was suspended in Laemmli Buffer and boiled. For the detection samples were separated by 
8 % SDS-PAGE and western blotting protocol.  
4.9 Cell viability (study III) 
The toxicity of acute exposure to RSV was measured in human primary myotubes or L6 
myotubes using the compound 3- (4,5- Dimethylthiazol- 2- yl)- 2,5- diphenyl tetrazolium 
bromide (MTT). The MTT test measures the formation of formazan by the mitochondrial 
dehydrogenases, and therefore it has also been used as a test of mitochondrial function 
(Morino, Petersen et al. 2012). Absorbance of the purple formazone (the reduced MTT 
which is formed in the living cells) was measured at the wavelength of 560 nm, with 
background substraction at 650 nm.  
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4.10 AMPK activity (study III) 
The activity of AMPK isoform complexes α1/β2/γ1 and α2/β2/γ1 was measured to assess 
the effect of RSV. AMPK (300 ng per reaction) was incubated with the SAMS synthetic 
peptide substrate (HMRSAMSGLHLVKRR) (250 µg/ml), AMP (125 mM) and the 
compound of interest for 2 h at 30 oC. The reaction was initiated by adding 250 µM [33P]-
ATP Assay Cocktail (50 µM ATP, 5 Ci/nmol [33P]-ATP per reaction). The reaction was 
terminated on P81 paper strips, followed by washing with 1% phosphoric acid and 
measurement of the radioactivity in the β-counter. 
4.11 Muscle ATP and PCr concentrations 
To confirm the viability of the muscle strips in study IV ATP and PCr concentrations were 
measured. Intact muscle strips were incubated up to 360 min in KHB at 35oC with or 
without 1 mM palmitate. ATP and PCr concentrations were assessed by Lowry’s 
fluorometric method with modification (Lowery 1972).  
4.12 Statistics 
4.12.1 Statistics used for intact skeletal muscle strips (studies I,II) 
All data are presented as mean ± SEM. Paired and unpaired Student´s t-tests were used to 
analyse paired and unpaired data, respectively. All statistical analysis were performed with 
SPSS statistical package (Version 13.0) (studies I,II) or with Prism statistical software 
(study IV). P < 0.05 was considered significant. 
4.12.2 Statistics used in cell culture models (study III) 
All data are presented as mean ± SEM from at least three independent experiments. The 
data were analyzed with one-way ANOVA with repeated measurements followed by 
Tukey´s post hoc test. P < 0.05 was considered significant. 
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5 Results and discussion 
5.1 Characteristics of the models used in the study. 
In the current study, two models of skeletal muscle were used: human muscle strips and 
human primary muscle cells. These models enable the use of strictly controlled incubation 
conditions. However, as isolated human muscle strips maintain the composition of intact 
and mature muscle tissue, this model more closely simulates physiological in vivo 
conditions. This is an advantage over human primary muscle cells. On the other hand, the 
viability of the human muscle strips is severely compromised after prolonged incubations 
(Zierath 1995). Thus, this model can only be used in acute experiments. Human primary 
muscle cells are more suitable to study the effect of chronic perturbations, and the amount 
of available material usually does not create experimental limits. As human primary 
muscle cells express all the insulin signaling components (Al-Khalili, Kramer et al. 2004) 
and are able to sustain their diabetic phenotype in culture (Gaster, Petersen et al. 2002), 
they are an important additional research tool to study muscle metabolism.  
5.1.1 Viability of the human muscle strips  
ATP and PCr concentrations at the beginning of the incubation (0 h) were 20.23±1.14 
µM/g dry wt and 62.81± 5.19 µM/g dry wt, respectively; and decreased slightly after 6 h 
incubation to 15.32 ±1.19 µM/g dry wt and 57.57± 2.72 µM/g dry wt, respectively (n=5) 
(Figure 5, Skrobuk et al. unpublished). Incubation with palmitate for 6 h did not affect 
ATP and PCr concentrations (14.53± 1.28 µM/g dry and 56.15± 3.45 µM/g dry, 
respectively n=3). These data confirm that the muscle strips were viable within the time-
frame and experimental set-up of our experiment.  
5.1.2 Human primary muscle cells (study III) 
To confirm the formation of myotubes we analysed the expression of the muscle specific 
transcription factor myogenin using immunocytochemistry.  Moreover, we also assessed 
the expression of desmin, a structural protein specific for muscle cells, and the expression 
of myogenin using western blotting technique. Myogenin expression was transiently 
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increased with a maximum at 3 d and return to basal at 7 d (Fig 6A and Fig 6B). Desmin 
expression increased gradually during the differentiation period, with the maximum 
reached at day 7 (Figure 6 B). Thus, we chose to differentiate muscle cells for 7 days in 
our studies. 
 
Figure 5. ATP and PCr concentrations over time in isolated human muscle strips 
(Skrobuk et al. unpublished). Muscle strips from 5 men were incubated in KHB for 0, 2 
(n=1), or 6 h, and ATP and PCr concentrations were determined as described in the Methods 
(4.11).   
 
5.2 The effect of adiponectin on glucose transport in human 
skeletal muscle (study I) 
A decrease in circulating levels of adiponectin has been shown in insulin resistant states 
such as obesity and type 2 diabetes (Hotta, Funahashi et al. 2000). Interestingly, 
therapeutic approaches to improve insulin sensitivity, such as TZDs, are associated with 
increased adiponectin concentrations (Yu, Javorschi et al. 2002). Exposure to the globular 
head of adiponectin increases 2-deoxyglucose uptake in isolated EDL muscle from rat 
(Tomas, Tsao et al. 2002). These data are in good agreement with our study. We observed 
that globular adiponectin increased glucose transport by 1.3-fold in isolated skeletal 
muscle strips from type 2 diabetic men.  A similar effect of globular adiponectin has been 
reported in skeletal muscle from lean and obese women. In the study by Bruce et al. 
identical concentrations of insulin (120 nM) and globular adiponectin (2.5 µg/ml) to our 
study were used (Bruce, Mertz et al. 2005). A combination of globular adiponectin and 
insulin had an additive effect on glucose transport in skeletal muscle obtained from lean 
 
 
 
 
57 
and obese women. However, this effect was reduced in skeletal muscle from obese 
subjects, suggesting existence of adiponectin resistance (Bruce, Mertz et al. 2005). We did 
not detect any further changes in glucose transport in muscle strips exposed to globular 
adiponectin and insulin, beyond that observed with insulin alone. Glucose transport may  
 
Figure 6. Analysis of the muscle specific markers expressed in primary human 
muscle cells during the differentiation period. A. Immunocytochemistry of the myogenin 
expression. B. Representative western blot of myogenin and desmin expression.  
 
already have been maximally stimulated in our subjects in response to pharmacological 
insulin concentration (120 nM). On the other hand, exposure to AICAR enhanced insulin 
action on glucose transport in skeletal muscle from type 2 diabetic men by 52 % and in 
healthy men by 31 %, which is in good agreement with previous report where exposure to 
AICAR improved insulin-stimulated glucose transport in type 2 diabetic skeletal muscle 
(Koistinen, Galuska et al. 2003). Gender affects adiponectin concentrations, with higher 
levels observed in women (Fernandez-Real, Lopez-Bermejo et al. 2003). We recruited 
only men, whereas Bruce et al. studied women. Thus, the lack of insulin-sensitizing action 
of globular adiponectin in our population may have been related to gender. Finally, 
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considering that only a 30 % increase in glucose transport was observed in our study and 
by Bruce et al. (Bruce, Mertz et al. 2005), an acute elevation of adiponectin concentration 
may play a minor role in the regulation of glucose metabolism in human skeletal muscle. 
5.3 The effect of adiponectin on canonical insulin signaling 
pathway (study I) 
Adiponectin increases insulin-mediated activation of AKT via APPL1 in C2C12 cells 
(Mao, Kikani et al. 2006). To explore the role of adiponectin in human skeletal muscle, we 
tested if globular adiponectin stimulates phosphorylation of AKT at Ser 473 and Thr308.  
Globular adiponectin did not affect AKT phosphorylation at either residue in either of our 
study groups, which is in line with data from C2C12 cells (Mao, Kikani et al. 2006). 
Insulin stimulation increased phosphorylation of AKT at Ser473 and Thr308 similarly in type 
2 diabetic and nondiabetic muscle.  Globular adiponectin did not have any further effect 
on insulin-stimulated AKT phosphorylation. Our data are opposite to those reported in 
C2C12 myotubes, where adiponectin had an additive effect on the insulin-stimulated 
phosphorylation of AKT at Thr308. Taken together, adiponectin might have different 
effects depending on the study model used. Our signaling data are in line with the glucose 
transport results: adiponectin did not have any further effect on insulin action on glucose 
metabolism. Considering the lack of adiponectin on AKT phosphorylation in the basal 
state, globular adiponectin appears to stimulate glucose transport in type 2 diabetic muscle 
via signaling pathways distinct from AKT. 
5.4 The expression of adiponectin receptors in skeletal 
muscle from type 2 diabetic and healthy men (study I) 
Adiponectin receptors, AdipoR1 and R2, are both abundantly expressed in skeletal 
muscle. AdipoR1 plays the main role in adiponectin action in skeletal muscle (Chen, 
McAinch et al. 2005; Yamauchi, Nio et al. 2007). AdipoR1 mediates adiponectin 
signaling via AMPK, whereas AdipoR2 signals via PPARα (Yamauchi, Nio et al. 2007). 
Studies examining adiponectin receptor expression in human skeletal muscle are 
controversial. mRNA expression for both adiponectin receptors has been reported to be 
similar in obese type 2 diabetic and lean nondiabetic subjects in skeletal muscle (Debard, 
Laville et al. 2004) or in cultured myotubes (Chen, McAinch et al. 2005). Blüher et al. 
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have reported higher skeletal muscle adiponectin receptor 1 and 2 mRNA expression in 
obese type 2 diabetic and IGT subjects than lean normoglycaemic people (Bluher, Bullen 
et al. 2006). In our study, we examined the protein expression of adiponectin receptors in 
type 2 diabetic and non-diabetic muscle. The expression of AdipoR1 and AdipoR2 was 
similar between both groups. Thus, changes in AdipoR expression do not account for 
differences in metabolic responses to globular adiponectin between the two study groups.  
5.5 The effect of adiponectin on AMPK signaling (study I) 
Globular adiponectin activates the AMPK signaling pathway and stimulates glucose 
uptake in C2C12 cells (Yamauchi, Kamon et al. 2002). In addition, effect of adiponectin 
on AMPK activity was observed in human primary muscle cells (Chen, McAinch et al. 
2005). Therefore, to identify a possible molecular mechanism of adiponectin action in 
human skeletal muscle, we next analyzed the effect of globular adiponectin on 
phosphorylation of AMPK. Phosphorylation of AMPK was unchanged after a 60 min 
exposure to globular adiponectin in type 2 diabetic. In nondiabetic muscle AMPK 
phosphorylation was slightly decreased following exposure to globular adiponectin. 
AICAR increased phosphorylation of AMPK by 11 % in non-diabetic muscle, as 
expected. Activation of AMPK in C2C12 myotubes was reported after 15 min incubation 
with globular adiponectin (Yamauchi, Kamon et al. 2002). In rat skeletal mucle activation 
of AMPK in response to globular adiponectin was transient and returned to basal after 60 
min exposure to adiponectin (Tomas, Tsao et al. 2002). Thus, phosphorylation of AMPK 
could possibly have occurred at an earlier time point in our study.  
5.6 The effect of rosiglitazone on insulin action and glucose 
transport in human skeletal muscle (study II) 
Despite clinical safety concerns and withdrawal of rosiglitazone from the pharmaceutical 
market, TZDs remain an excellent research tool to develop novel and improved 
therapeutical strategies to treat insulin resistance. The molecular mechanisms whereby 
TZDs improve insulin sensitivity are still incompletely understood. TZDs are high affinity 
ligands for PPARγ, a transcription factor highly expressed in adipocytes and also to some 
extent in other tissues such as skeletal muscle (Vidal-Puig, Considine et al. 1997). 
However, the effects of TZDs on PPARγ and adipocytes do not exclude the possibility 
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that TZDs may also act via different signaling mechanisms in other tissues. Acute 
exposure of rat EDL muscle to troglitazone increases 2-deoxyglucose uptake and 
palmitate oxidation, as well as activates AMPK (LeBrasseur, Kelly et al. 2006). Since 
chronic treatment with TZDs improves insulin action in humans (Tiikkainen, Hakkinen et 
al. 2004; Skov, Glintborg et al. 2008), we examined whether TZDs had an acute effect 
directly in intact human skeletal muscle. Exposure for 60 min to rosiglitazone did not 
modify basal or insulin-stimulated glucose transport. Although we observed a tendency to 
improve glucose transport rate in response to higher rosiglitazone concentration (10 µM), 
this was not statistically significant (p = 0.182).  Furthermore, we analysed if the clinical 
characteristics of the study cohort would affect responses to rosiglitazone. Rosiglitazone 
did not modify glucose transport in the absence or presence of abnormal glucose 
metabolism, overweight or compromised physical fitness. We used 60 min exposure time 
to study the effect of rosiglitazone on glucose transport. Thus, it cannot be excluded that a 
longer incubation time would have been needed to see an effect in human skeletal muscle. 
On the other hand, exposure of isolated mouse muscle for 5 h to a TZD does not modify 
insulin-stimulated 2-deoxyglucose uptake (Zierath, Ryder et al. 1998). Moreover, our 
study is in line with the lack of an acute stimulation of 3-O-methyl glucose transport by 
troglitazone in L6GLUT4myc cell line (Konrad, Rudich et al. 2005). Interestingly, 2-
deoxyglucose uptake was increased in response to troglitazone due to stimulation of 2-
deoxyglucose phosphorylation in L6GLUT4myc myotubes, suggesting that metabolic flux 
via hexokinase was increased (Konrad, Rudich et al. 2005). We used 3-O-methylglucose 
in our study. Therefore, we could only measure the glucose transport step, because 
hexokinase is not able to phosphorylate 3-O-methylglucose. In contrast, 2-deoxyglucose 
uptake reflects both glucose transport and phosphorylation steps. Thus, we cannot exclude 
that rosiglitazone might acutely stimulate glucose fluxes downstream of the glucose 
transport step in human skeletal muscle. To study the effect of rosiglitazone on insulin 
sensitivity we tested if exposure to rosiglitazone affected proximal insulin signaling 
events. As reflected by unchanged basal or insulin-stimulated phosphorylation of AKT at 
Ser 473 and Thr308, rosiglitazone did not affect insulin signaling events in our study.  
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5.7 The effect of rosiglitazone on the AMPK signaling 
pathway (study II) 
Emerging evidence suggests that one of the mechanisms whereby TZDs stimulate glucose 
uptake and lipid metabolism is via the AMPK signaling cascade. TZDs have been shown 
to activate AMPK in H-2Kb muscle cells (Fryer, Parbu-Patel et al. 2002) and 
L6GLUT4myc myotubes (Konrad, Rudich et al. 2005). Moreover, a decrease in the 
expression of AMPK using siRNA inhibits the stimulation of 2-deoxyglucose uptake by 
troglitazone (Konrad, Rudich et al. 2005). Increased glucose uptake and palmitate 
oxidation in response to TZDs was demonstrated in intact skeletal muscle from rat and it 
coincided with rapid activation of AMPK (LeBrasseur, Kelly et al. 2006). We analyzed 
whether rosiglitazone directly activates AMPK in intact human skeletal muscle. Exposure 
to 10 µM rosiglitazone transiently increased ACC phosphorylation in nondiabetic muscle. 
Phosphorylation reached a peak at 15 min (p = 0.051, n = 5), suggesting AMPK activation 
by acute exposure to rosiglitazone.  The time course results observed in our studies were 
similar to rodent muscle, where a peak in AMPK activity and ACC phosphorylation 
following exposure to 5 µM troglitazone occurs between 5 and 15 min, with a return to 
baseline within 60 min (LeBrasseur, Kelly et al. 2006). Acute AMPK activation by 
rosiglitazone did not coincide with stimulation of glucose transport in our study. However, 
it is possible that rosiglitazone might acutely modify lipid metabolism via the AMPK-
ACC signaling pathway in intact human skeletal muscle. 
 
5.8 The effect of resveratol on glucose and fatty acid 
metabolism in human skeletal muscle  (study III) 
The natural polyphenolic compound resveratrol has recently attracted considerable 
scientific interest due to its antidiabetic properties. There is evidence for RSV to improve 
insulin action and whole body glucose homeostasis in animal models (Lagouge, Argmann 
et al. 2006; Um, Park et al. 2010). Treatment with RSV has also been linked with the 
reduction of fat content and body weight in rodents (Su, Hung et al. 2006; Um, Park et al. 
2010). However, the molecular mechanisms of RSV action on glucose and lipid 
metabolism in human skeletal muscle have not been established. Therefore, we examined 
the metabolic effects of RSV in human primary muscle cells. In the basal state, glucose 
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uptake was unaffected by the presence of 100 µM RSV. However, the insulin-stimulated 
glucose uptake was decreased by 34 %. To further explore the effects of RSV on glucose 
metabolism, we measured glucose incorporation into glycogen. Exposure to RSV 
significantly reduced basal as well as insulin-stimulated glycogen synthesis. Our data were 
surprising, because RSV stimulates glucose uptake in L6 muscle cells in a dose-dependent 
fashion, with the maximum response seen at 100 µM (Breen, Sanli et al. 2008; Minakawa, 
Kawano et al. 2011). Since our data differed from those obtained in L6 muscle cells, we 
examined if the effects of 4h exposure to RSV are concentration- or species dependent. In 
human myotubes, basal glucose uptake was increased with lower RSV concentrations (1 
and 10 µM). Moreover, we observed an inhibition of basal and insulin- stimulated glucose 
uptake by higher RSV concentrations (100-200 µM). We also performed dose-response 
experiments using 0.1-100 µM RSV in L6 myotubes. RSV at 0.1-100 µM did not affect, 
while 200 µM RSV inhibited basal glucose uptake. Similar to human myotubes there was 
an inhibition of insulin-stimulated glucose uptake at 100-200 µM. The reason for different 
findings between our study and studies by Breen et. al. or Minakawa et al. is unclear, but 
cannot be explained by different concentrations of RSV or duration of RSV exposure. 
Possible species differences may also be excluded, since we observed similar inhibitory 
effect of higher doses of RSV on glucose uptake in both human and L6 myotubes.  It is 
worth noticing that lower concentrations of RSV enhanced basal glucose uptake in human 
myotubes, while higher concentrations had the opposite effect. Thus, our data fit well with 
the concept of hormesis, with lower concentrations of RSV having a positive and higher 
ones a negative biological effect (Hawley, Burke et al. 2011). 
 
RSV exerts beneficial effects such as weight reduction and reduced fat accumulation. 
Moreover, RSV has been shown to increase mitochondrial biogenesis as well as physical 
endurance in rodents (Lagouge, Argmann et al. 2006; Um, Park et al. 2010). These data 
suggest that RSV impacts lipid metabolism. Thefore, we examinated if acute exposure to 
RSV affects lipid metabolism in human skeletal muscle. First, we determined fatty acid 
oxidation, using only a trace amount of radioactive palmitate in the media (without any 
cold palmitate).  Curiously, insulin increased palmitate oxidation. This most likely was 
due to stimulatory effect of insulin on palmitate uptake (Bouzakri, Austin et al. 2008). As 
expected, acute exposure of human myotubes to AICAR increased palmitate oxidation, 
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whereas presence of AMPK inhibitor compound C significantly decreased palmitate 
oxidation. In the presence of resveratrol, palmitate oxidation was reduced by 40 %. We 
also performed fatty acid oxidation experiments using physiological palmitate 
concentration (0.2 mM). Also in this experimental set-up, acute exposure of human 
muscle cells to RSV led to a decrease in palmitate oxidation. Taken together, our data on 
both glucose and lipid metabolism suggest that RSV may act as a metabolic inhibitor in 
human skeletal muscle cells.  
5.9 The effect of RSV on insulin signaling (study III)   
Resveratrol reversed palmitate-induced insulin resistance in C2C12 cells (Sun, Zhang et 
al. 2007). Initially, we hypothesised that exposure to RSV could counteract palmitate-
induced insulin resistance in human muscle cells. However, we observed an impairment in 
glucose and lipid metabolism in the presence of RSV. To gain more insight into the 
mechanisms of RSV action, we investigated if RSV affects insulin signaling. We observed 
a decrease in insulin-stimulated phosphorylation of AKT, an effect sustained for 24 h. 
These data were consistent with the negative effects of RSV on glucose uptake and 
glycogen synthesis. The inhibitory effect of RSV on glucose uptake or insulin signaling 
has previously been reported. RSV has been shown to be a direct inhibitor of class IA PI3-
kinase in primary human myotubes (Frojdo, Cozzone et al. 2007). RSV reduced insulin-
stimulated AKT Ser473 phosphorylation in rat L6 and human rhabdomyosarcoma CCL 
muscle-derived cells in a dose-dependent fashion. Insulin-stimulated glucose uptake was 
decreased by 82.7% also in 3T3-L1 adipocytes by 100 µM RSV (Frojdo, Cozzone et al. 
2007). Dose-dependent inhibition of basal glucose uptake by RSV was reported in two 
myelocytic cell lines, U937 and HL-60 cells. Finally, RSV was reported to act as an 
inhibitor of insulin stimulated AKT phosphorylation in H4IIE cells (a rat hepatoma cell 
line), HepG2 cells (a human hepatoma cell line) and primary rat hepatocytes (Zang, Xu et 
al. 2006). Taken together, RSV inhibits glucose metabolism and insulin signaling in 
several different cell models.  
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5.10 The inhibitory effect of RSV on AMPK signaling in 
human myotubes (study III) 
Several lines of evidence suggest activation of AMPK by RSV (Zang, Xu et al. 2006; 
Frojdo, Cozzone et al. 2007; Breen, Sanli et al. 2008; Um, Park et al. 2010). Therefore, we 
investigated if RSV activates the AMPK pathway in human primary muscle cells. Acute 
exposure to 100 µM RSV reduced phosphorylation of AMPK and ACC, suggesting a 
inhibition of AMPK signaling. The inhibitory effect of RSV on the AMPK signaling 
cascade was maintained for 12 h with a return to basal levels by 24 h. The inhibition of 
AMPK signaling is in line with the inhibitory effect of RSV on palmitate oxidation in our 
study.  We also have investigated the dose-dependent effect of RSV on AMPK signaling 
in human myotubes and L6 cell line. We observed that RSV decreased AMPK 
phosphorylation already at the concentration of 1 µM in human muscle cells.  
Phosphorylation of ACCβ was not affected with the lower concentration of RSV, whereas 
higher RSV concentrations (100-200 µM) reduced ACCβ phosphorylation in human 
myotubes. Interestingly, RSV increased phosphorylation of ACCβ in L6 myotubes at all 
concentrations used, suggesting some species differences in response to RSV. PGC-1α is 
deacetylated and thus activated by Sirt1 (Lagouge, Argmann et al. 2006). Since Sirt1 
activation by RSV requires AMPK activity (Um, Park et al. 2010), we also analysed PGC-
1α acetylation. Acute exposure to 1 µM RSV significantly increased acetylation of PGC-
1α in human primary myotubes. These data suggest reduction of SIRT1 activity by RSV. 
Since Sirt1 resides downstream of AMPK, these data would support the idea that RSV 
directly inhibits AMPK activity in human primary muscle cells. To confirm or refute this 
hypothesis, we next investigated the direct effect of RSV on AMPK activity by 
performing in vitro kinase assays. We used α1/β2/γ1 and α2/β2/γ1 isoforms, which are the 
major complexes of AMPK in skeletal muscle (Wojtaszewski, Birk et al. 2005). RSV at 
lower (1 µM) concentration blocked AMPK-α1 activity by 35% and AMPK-α2 activity 
by 50% (n=2), whereas higher RSV concentration (100 µM) completely inhibited the 
activity of both AMPK isoform complexes. In summary, our data suggest that acute 
treatment with RSV inhibits AMPK activity in human skeletal muscle cells. Since 30-day 
treatment with RSV results in increased phosphorylation of AMPK in human skeletal 
muscle (Timmers, Konings et al. 2011), it is possible that resveratrol has different effects 
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depending on the duration of the exposure. However, it is also possible that increased 
AMPK phosphorylation following 30-d peroral RSV treatment is a secondary 
phenomenon.  
5.11 The effect of acute exposure to RSV on ER stress 
(study III) 
We examined the effect of RSV on ER stress using eIF2α phosphorylation or CHOP 
expression as readouts. Interestingly, we observed increased eIF2α phosphorylation and 
CHOP expression after treatment with RSV in a dose-dependent manner. These data 
suggest that RSV induces ER stress in muscle cells. RSV had a similar effect on eIF2α 
phosphorylation and CHOP expression in L6 myotubes. Importantly, exposure to AICAR 
decreased eIF2α phosphorylation in human myotubes, suggesting that AMPK activation 
alleviates ER stress. This is combatible with previous data suggesting activation of AMPK 
decreases ER stress (Hwang, Chang et al. 2010). Therefore, the effects of AICAR and 
other AMPK activators on ER stress should be studied in more detail, as this may reveal 
novel targets for developing pharmaceutical therapies to treat insulin resistance.  
 
5.12 The effect of palmitate on glucose metabolism and 
insulin signaling in isolated human skeletal muscle strips 
(Unpublished data) 
Acute exposure to palmitate induced insulin resistance and activated ER stress signaling in 
human myotubes (Study III). Isolated skeletal muscle strip preparation resembles intact 
skeletal muscle more closely than primary cultured myotubes for example in terms of 
GLUT4 expression (Sarabia, Lam et al. 1992), and therefore the use of isolated skeletal 
muscle strips is an important complementary research tool in studies on muscle 
metabolism. To gain more insight into the interaction of palmitate and glucose 
metabolism, we next investigated the acute effects of high physiological palmitate 
concentration (1 mM) on glucose metabolism and insulin signaling in isolated human 
skeletal muscle strips (Skrobuk et al. unpublished). First, we studied the effect of 4 h pre-
exposure to palmitate on glucose transport and glycogen synthesis in intact skeletal 
muscle strips. Insulin at pharmacological concentration of 120 nM is often used in studies 
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in isolated muscle strips to stimulate the system maximally (Koistinen, Galuska et al. 
2003; Bruce, Mertz et al. 2005; Karlsson, Ahlsen et al. 2006). However, this concentration 
is 200-400-fold higher than observed postprandially for example during oral glucose 
tolerance test where maximal plasma insulin concentration varies 0.2 to 0.9 nM, 
depending on the degree of the insulin resistance of the subject. Insulin at extremely high 
concentrations might prevent detection of subtle impairments in insulin action following 
experimental perturbations such as exposure of muscles to palmitate. Thefore, here we 
chose to use high physiological insulin concentration (1.2 nM), which is close to ED50 (1 
nM) of the insulin receptor in human skeletal muscle (Argyraki, Wright et al. 1989). 
Muscle strips were obtained from 27 nondiabetic men (age 48±2, BMI 26±0.7, fasting 
glucose 5.6±0.07). Insulin increased glucose transport 1.7-fold (from 0.87±1.1 to 1.4±0.17 
nmol/mg/20 min, p<0.001). In muscle strips pre-exposed to palmitate for 4 h, basal 
glucose transport rate was increased (1.0±0.11 nmol/mg/20 min), insulin-stimulated 
glucose transport was unchanged (1.4±0.12), and insulin action on glucose transport 
(insulin-stimulated minus basal) reduced by 35 % (p = 0.086). 
Palmitate (2 mM) impairs insulin-stimulated glucose transport in isolated muscle strips 
from obese women, whereas it was without a significant effect in lean women (Thrush, 
Heigenhauser et al. 2008). Therefore, to investigate whether the effect of palmitate is 
modified by body weight, we divided our subjects into 2 groups: lean (BMI <25 kg/m2) 
and overweight (BMI>25 kg/m2). The negative effects of palmitate on glucose transport 
were more apparent in skeletal muscle strips from overweight compared to lean men, and 
appeared to involve an increase in basal glucose transport since insulin-stimulated glucose 
transport was unaffected (Figure 7a, Skrobuk et al. unpublished). Thus, these data are 
consistent with the previous report and suggest that overweight/obese muscle may be 
more susceptible for the ability of palmitate to evoke significant impairments in glucose 
transport (Thrush, Heigenhauser et al. 2008). Formation of ceramides might play an 
important role in palmitate-induced insulin resistance. Thus, we tested if blocking SPT 
with myriocin could protect muscles from lipid-induced insulin resistance. Co-incubation 
with myriocin protected muscle from palmitate induced insulin resistance  (Figure 7b, 
Skrobuk et al. unpublished). 
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Figure 7. Glucose transport. a) Glucose transport by body weight was analysed in muscle 
strips from 8 lean men and 12 overweight men using 3-O-methyl [3H] glucose. * p<0.05 vs 
respective control. ^ p<0.05 vs respective condition in the lean group. Data are presented as 
means±SEM (Skrobuk et al. unpublished). b) The effect of SPT inhibition on glucose 
transport. Glucose transport was measured in the absence or presence of 1 mM palmitate or 
myriocin (10µM) or 1.2 nM insulin. Data are expressed as delta (respective insulin 
stimulated condition – respective control). Data are presented as means±SEM n = 6 
(Skrobuk et al. Unpublished). 
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Our data are in line with animal studies, where myriocin-treated animals were protected 
against saturated fatty acid-induced insulin resistance (Holland, Brozinick et al. 2007). 
However, to confirm the role of ceramides in lipid-induced insulin resistance in human 
skeletal muscle, a metabolomic study would be needed to be performed. Saturated fatty 
acids decrease insulin-stimulated glycogen synthesis in vitro in rat and human muscle 
(Thompson, Lim-Fraser et al. 2000). These data are in good agreement with our findings, 
as we observed 18 % decrease in insulin-stimulated glucose incorporation into glycogen in 
muscle strips pre-exposed to palmitate (Figure 8, Skrobuk et al. unpublished). 
Collectively, these data indicate that palmitate induces insulin resistance and ceramides 
might play an important role in this process.  
 
Figure 8. Glycogen synthesis. Skeletal muscle strips from 9 nondiabetic men were 
incubated with or w/o 1 mM palmitate and 1.2 nM insulin for 4 h. Glucose incorporation into 
glycogen was measured as the amount of [14C]-glucose incorporated into glycogen during 
one hour. ** p<0.01, * p<0.05 vs respective control (Skrobuk et al. unpublished). 
 
Insulin-stimulated AKT-Ser473 phosphorylation is unaffected in lipid-induced insulin 
resistance in in vivo human studies (Storgaard, Jensen et al. 2004). These data are in 
accordance with our present findings: insulin-stimulated AKT at Ser473 phosphorylation 
was not impaired following exposure to palmitate (Skrobuk et al. data not shown). 
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Palmitate exposure (2 mM) reduced insulin-stimulated phosphorylation of AS160 in intact 
skeletal muscle from obese but not lean women (Thrush, Heigenhauser et al. 2008). 
Similarly, we observed that phosphorylation of AS160 was unaffected by 1 mM palmitate 
in lean muscles, whereas in muscles from overweight men, insulin action on AS160 
phosphorylation was abolished by palmitate pre-exposure (Figure 9, Skrobuk et al 
unpublished). Thus, our data provide evidence that overweight muscle is more suspectible 
to defects in insulin signaling when challenged with fatty acids. Interestingly, our data 
agree with observations on insulin signaling in T2D muscle, where AKT-Ser473 
phosphorylation is normal, while AKT-Thr308 and AS160 phosphorylations are impaired 
(Karlsson, Zierath et al. 2005). These data raise the possibility that impaired AS160 
phosphorylations in T2D muscle may be secondary to increased circulating FFA levels 
and/or increased muscle fat content. 
 
 
Figure 9. AS160 phosphorylation. AS160 phosphorylation was determined at the end of 
the glucose transport protocol in muscles strips from lean (n=5) and overweight men (n=10). 
AS160 phosphorylation has been expressed in relation to total AS160. The representative 
blot is from one gel. * p<0.05 vs respective control (Skrobuk et al. unpublished). 
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5.13 Palmitate and ER stress  
Endoplasmic reticulum (ER) stress has recently emerged as a major player in insulin 
resistance (Ozcan, Cao et al. 2004). Acute exposure of human myotubes to palmitate 
induced ER stress (Study III). Thus, we examined if palmitate activates ER stress in intact 
human skeletal muscle. The effect of palmitate on the PERK signaling arm of the UPR 
was studied by determining phosphorylation of eIF2α (Harding, Zhang et al. 1999; Ma, 
Brewer et al. 2002). In skeletal muscle strips from lean men, there was no change in the 
phosphorylation of eIF2α in response to palmitate. However, when muscles from 
overweight men were exposed to palmitate, the phosphorylation of eIF2α was 
significantly increased (Figure 10, Skrobuk et al. unpublished). After 4 h exposure to 
palmitate, there was also a marked increase in chaperon protein BiP/ GRP78 levels in 
muscle strips from overweight, but not from lean men. These data provide evidence that 
overweight human skeletal muscle is suspectible to ER stress in response to palmitate, 
while lean muscle seems to be able to cope with palmitate excess and resolve ER stress. 
JNK, which is activated via IRE1(Urano, Wang et al. 2000), phosphorylates IRS at 
inhibitory serine residues and thus leads to defects in the insulin-signaling pathway(Sabio, 
Kennedy et al. 2010). Therefore, in the future it will be interesting to test the link between 
ER stress and insulin signaling pathway in human skeletal muscle.  
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 Figure 10. Phosphorylation of eIF2α and GRP78/BiP expression. Skeletal muscle 
strips from 5 lean and 10 overweight men were incubated with or without 1 mM palmitate 
and phosphorylation of eIF2α and GRP78/BiP levels were measured at the end of the glucose 
transport protocol. Representative blots are presented. For clarity, only basal and palmitate 
stimulated data are quantified.  * p<0.05 vs respective condition w/o palmitate (Skrobuk et 
al. unpublished).  
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6 Summary 
The results of the studies can be summarised as follows:  
1. Acute exposure to globular adiponectin stimulates glucose transport in skeletal 
muscle from type 2 diabetic men. This is related neither to insulin nor AMPK 
signaling pathways.  
2. Acute exposure to rosiglitazone does not affect glucose transport or insulin 
signaling in human skeletal muscle. However, rosiglitazone transiently activates 
AMPK signaling.  
3. Palmitate impairs glucose metabolism and increases ER stress in isolated skeletal 
muscle as well as in human primary muscle cells. Acute exposure to resveratrol 
inhibits glucose and lipid metabolism, and directly inhibits AMPK activity in 
human skeletal muscle cells. Resveratrol does not prevent palmitate-induced 
insulin resistance. Exposure to resveratrol increases and exposure to AICAR 
reduces ER stress, respectively. 
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7 Conclusions and future perspectives 
Insulin resistance, particularly in skeletal muscle, is the hallmark of type 2 diabetes 
mellitus. Therefore, it is important to understand at molecular level what are the 
mechanisms and intracellular events that impair insulin signaling and eventually 
metabolism, as this may identify novel therapeutical targets to improve insulin action. 
Here, we observed a stimulatory effect of globular adiponectin on glucose transport in 
type 2 diabetic muscle. However, the effect was modest and therefore skeletal muscle may 
not be the primary target of the insulin-sensitizing effect of adiponectin. Similarly, acute 
exposure to rosiglitazone, a TZD, failed to impact on glucose transport in human skeletal 
muscle. These data support the notion that the primary target of TZDs is adipose tissue, 
and the increase in insulin sensitivity in skeletal muscle and liver would be secondary to 
improved adipocyte function.  
 
The polyphenolic compound resveratrol acts acutely as a metabolic inhibitor in human 
skeletal muscle. Therefore, any beneficial effects of resveratrol appear to be secondary, 
and further human studies on the effects of resveratrol and its mechanisms of action are 
warranted. Our results add AMPK among the many intracellular kinases that are directly 
inhibited by resveratrol. Acetylation/deacetylation of proteins may play an important role 
in the insulin signaling pathway (Pirola, Zerzaihi et al. 2012). Thus, this concept should be 
tested in future studies using compounds like resveratrol, as protein 
acetylation/deacetylation might be a promising target to design new pharmacological 
compounds to treat T2DM. Palmitate induces insulin resistance and ER stress both in 
primary human myotubes as well as in intact human muscle strips. AICAR reduces ER 
stress in human muscle cells. Therefore targeting ER stress via the AMPK pathway may 
be beneficial in treating metabolic diseases. However, more experiments with AMPK 
activators would be needed to confirm this concept. In addition, to clarify the involvement 
of ER stress in insulin resistance in skeletal muscle and T2DM, experiments using ER 
stress alleviating chemical chaperons such as 4-PBA and TUDCA should be tested to 
combat excess nutrient or cytokine induced insulin resistance.   
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Acute exposure to palmitate impairs proximal insulin signaling and affects glucose 
metabolism in skeletal muscle from overweight men. This is associated with sustained ER 
stress. The negative effect of palmitate is also seen in human primary muscle cells. Thus, 
more signaling experiments are called for to describe mechanism of palmitate-induced 
insulin resistance in skeletal muscle, as various intracellular sensors, for example stress 
kinases such as JNK and inhibitory IRS1-Ser312 phosphorylation may play a role. It is 
interesting to note that in contrast to overweight muscle, lean muscle seems to be able to 
cope with acute exposure to excess palmitate. Identification of the molecular mechanisms 
behind this adaptation may provide clues to the pathogenesis of T2DM, as well as insulin 
resistance induced by excess nutrients such as obesity.  
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